



Evaluation Report

NUMBER
MDA 02029

Anti-HCV commercial panel data (update 1)

Comparative performance data for anti-HCV assays using
commercial seroconversion and other panels

MDA Evaluation Report
MDA 02029



WHAT YOU CAN EXPECT FROM MDA EVALUATION REPORTS

The Device Evaluation Service (DES) aims to provide independent and objective evaluations of medical devices available on the UK market. Specialist centres, mainly in NHS Trusts, do the evaluations under long-term contract to, and in accordance with protocols approved by, the MDA. The evaluations are usually of a unit supplied by the manufacturer. We would expect this unit to be representative of the product on the market but cannot guarantee this. Prospective purchasers should satisfy themselves with respect to any modifications that might be made to the product type after MDA's evaluation. The reports are intended to supplement, not replace, information already available to prospective purchasers.

© Crown Copyright 2002

Apart from any fair dealing for the purposes of research or private study, or criticism, or review, as permitted under the Copyright, Designs & Patents Act, **1988**, this publication may only be reproduced, stored or transmitted in any form or by any means with the prior permission, in writing, of the Controller of Her Majesty's Stationery Office (**HMSO**).

Enquiries concerning reproduction outside those terms should be sent to **HMSO** at the undermentioned address:

**The Copyright Unit,
Her Majesty's Stationery Office,
St. Clements House,
2 - 16 Colgate,
NORWICH,
NR3 1BQ.**

Anti-HCV commercial panel data (update 1)

Christine S Burgess

Emma Delieu

Keith R Perry

Kevin Sallett

John V Parry

**Microbiological Diagnostics Assessment Service (MiDAS)
Sexually Transmitted and Blood Borne Virus Laboratory
Virus Reference Division
Central Public Health Laboratory
61 Colindale Avenue
LONDON
NW9 5HT**

Contents

Summary	2
Introduction	3
Reference tables	4
Anti-HCV seroconversion panel data	8
Anti-HCV performance panel data	32
RIBA HCV 3.0 immunoblot patterns for seroconversion and performance panels	37
References	43
Appendix	45
Contact details of manufacturer and/or UK agent	45
How to obtain MDA evaluation reports	47

Summary

The Medical Devices Agency funds an ongoing programme of diagnostic virology kit evaluations at MiDAS. These evaluations generate large quantities of comparative performance data which have been previously published in cumulative form as an appendix to each evaluation report. To avoid duplication of information and reduce the bulk of individual evaluation reports, detailed performance data are now published separately.

This document represents the second publication of anti-HCV seroconversion data and also includes data for four performance panels. Included in this are data from the first publication¹ in this anti-HCV series and also that from three further evaluations²⁻⁴ (Access HCV Ab Plus, AxSYM[®] HCV version 3 and Vitros *ECi* anti-HCV) that have since been undertaken at MiDAS.

Other publications in this series present data on kits for the detection of anti-HIV^{5,6} and HBsAg^{7,8} evaluated up to 2002.

■ Background

The joint Medical Devices Agency/Public Health Laboratory Service series of virology kit evaluations, performed at MiDAS, commenced in the summer of 1985 when the first five commercial anti-HIV (then called anti-HTLV III/LAV) enzyme immunoassay kits became available^{9,10}. In the ten years between 1987 and 1996 an average of four anti-HIV kits per annum, mostly 96-well microplate-based EIAs, were evaluated. In 1995, the first report on anti-HCV screening kits was published¹¹ which contained comparative data on 10 kits. During the last few years the market has broadened greatly such that, in addition to new and modified anti-HCV EIA kits, a wide range of automated, semi-automated and simple/rapid test devices are now available, many of which have been examined by MiDAS^{2-4, 12 and 13}.

In early evaluations only a small number of commercial seroconversion panels, comprising consecutive bleeds spaced several days apart from a seroconverting plasma donor, were available. In recent years, the number of commercially available seroconversion and other panels has increased enormously. The much more substantial data now generated enable us to draw more precise conclusions about real differences between screening kits in the detection of early HCV infection. These data and those generated by testing related performance panels, have been assembled in the collection of reference tables presented in this report. It is anticipated that readers will use these comprehensive data in conjunction with the MDA evaluation reports for specific assay kits.

Previous evaluations of anti-HCV kits^{2-4 and 11-13} have demonstrated that there is no 'gold standard' method capable of always identifying HCV status correctly. Consequently various confirmatory approaches were developed for testing screen reactive specimens by several additional assays¹⁴⁻¹⁶. Even when coupling several approaches, in certain cases, it can still prove difficult to assign HCV status with confidence.

■ Commercial panels

Comparative data are presented for 19 anti-HCV seroconversion panels and five performance panels from Boston Biomedica Inc (BBI), USA (pages 8 – 18 and 32 – 35) and 21 from BioClinical Partners Inc (BCP), USA (pages 18 – 31). Results are expressed as a ratio of the absorbance or signal given by the specimen to the cut-off value or equivalent. Ratios greater than or equal to 1.00 are considered reactive whereas ratios less than 1.00 are considered unreactive. Where possible we have included data from supplemental line assays *ie* RIBA HCV 3.0 (Ortho Clinical Diagnostics), INNO-LIA HCV Ab III (Innogenetics) and RNA amplification techniques *ie* AMPLICOR HCV monitor test (Roche Diagnostics) and Chiron bDNA HCV. These results were generated by other reference centres and provided to us by BBI or BCP.

All negative values have been shaded and are presented in bold typeface, whereas all positive values are presented in normal typeface.

● Seroconversion panels

The panels comprise a series of undiluted plasma samples, containing no preservatives, that were maintained in a frozen state, except when they were dispensed into vials prior to shipping to MiDAS. The panels are comprised of a series of samples collected from a single donor at the time of seroconversion for HCV. Each table shows the ‘days since first bleed’ which represents the number of days delay between each serial bleed and the initial plasma donation during seroconversion. It is not possible to determine the timing of the infection of the donor.

● Performance panels

Unlike the seroconversion panels, the performance panels are collections of donated specimens from many individuals, many of whom may have seroconverted shortly before their collection. As such, they provide a broader picture of how a kit copes with recent seroconverters and they have been used to distinguish further the sensitivity of the assays presented. The same criteria described above have been used to aid in the interpretation of the data provided.

Low titre panels, PHV103 and PHV104, mixed titre panels, PHV203 and PHV204, and worldwide panel, WWHV301, were prepared from the repository of frozen serum and plasma units at BBI. Specimens that were selected for panel PHV103 were reactive with less than maximum absorbance on at least two HCV EIA tests and the specimens included in panel PHV104 were reactive with less than maximum absorbance on one HCV EIA test. One negative plasma sample was included in each panel as a unreactive control. The specimens included in panels PHV203 and PHV204 were selected to demonstrate a variety of patterns and a range of reactivity with the HCV proteins represented in supplemental tests. Two specimens, one plasma and one serum, were included in each panel as an internal negative control. The specimens included in panel WWHV301 originated from Argentina, China, Egypt, Ghana, Uganda and the USA and were serotyped at BBI.

- **RIBA HCV 3.0 results**

RIBA HCV 3.0 has been regarded by many as the benchmark anti-HCV supplemental test. RIBA HCV 3.0 results are presented for all the commercial panel specimens described in the previous two sections (see pages 37 – 42). The following criteria were used to interpret the results:

Band pattern observed	Interpretation
No bands of 1+ or greater*	Unreactive
Two or more HCV-specific bands of 1+ or greater intensity	Reactive
Bands of 1+ or greater reactivity but pattern does not meet criteria for reactive**	Indeterminate
Note:	
* Reactivity of SOD band alone is considered unreactive.	
** 1+ or greater SOD reactivity in addition to antigen reactivity is considered indeterminate.	

- **Notes for tables**

Neg	negative
Ind	indeterminate
POS	positive
NA	not available
NK	not known
NT	not tested
ND	not detected
BLD	below limit of detection
BQR	below quantitative range
MEq/mL	MegaEquivalent/mL (approximately equal to 1 million equivalents of HCV RNA)
* ¹	Data taken from BBI data sheet
* ²	Data taken from BCP data sheet
* ²	PRISM failed to aspirate this specimen. No result was issued
* ³	The cut-off varies for channels A and B and is therefore different for each specimen

■ Index of commercial panels

BBI anti-HCV seroconversion panels	Page:
PHV901	8
PHV902	9
PHV903	9
PHV904	10
PHV905	11
PHV906	12
PHV907	12
PHV908	13
PHV909	14
PHV910	14
PHV911	15
PHV912	15
PHV913	16
PHV914	16
PHV915	17
PHV916	17
PHV917	18
BCP anti-HCV seroconversion panels	
SD976	18
6211	19
6212	20
6213	21
6214	22
6215	23
6216	23
6217 (false positive)	24
6219 (false positive)	25
6220 (false positive)	26
6222	26
6224	27
9041	27
9042 (false positive)	28
9043 (false positive)	28
9044	28
9045	29
9046	29
9047	30
9048 (false positive)	31
9049 (false positive)	31

BBI anti-HCV low / mixed-titre panels	Page:
PHV103 (low-titre)	32
PHV104 (low-titre)	33
PHV203 (mixed-titre)	34
PHV204 (mixed-titre)	35
BBI Worldwide anti-HCV performance panel	
WWHV301	36
RIBA HCV 3.0 immunoblots for BBI anti-HCV seroconversion panels	
PHV901 - 907	37
PHV908 - 915	38
RIBA HCV 3.0 immunoblots for BCP anti-HCV seroconversion panels	
6211 - 6216 and 6222	39
9041 and 9044 - 9047	40
RIBA HCV 3.0 immunoblots for BBI anti-HCV performance panels	
PHV103 - 104 and PHV203 - 204	41
RIBA HCV 3.0 immunoblots for worldwide HCV performance panels	
WWHV301	42

BBI Anti-HCV seroconversion panel PHV901 (genotype 1A)

Product name	Product number	Lot number	Panel ID Days since first bleed	PHV901-01	PHV901-02	PHV901-03	PHV901-04	PHV901-05	PHV901-06	PHV901-07	PHV901-08	PHV901-09	PHV901-10	PHV901-11	Cut-off
				0	65	97	99	104	106	131	139	159	166	203	
Abbott HCV 3rd generation EIA	7A16-23	83810 HP00	OD/CO	0.15	0.15	1.00	1.00	1.20	1.35	≥ 9.00	6.80	≥ 10.60	≥ 10.60	≥ 10.60	0.44
Access anti-HCV	34310	590802	S/CO	0.95	0.69	11.27	9.67	8.45	8.24	6.29	4.99	7.40	6.89	14.27	42593
Access HCV Ab PLUS	34330	194822	S/CO	0.05	0.04	5.11	5.41	5.84	5.74	8.33	8.22	8.50	8.29	9.20	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.36	0.22	56.88	50.17	57.23	57.67	75.67	65.99	70.80	69.65	95.90	8.90
IMx HCV	3A99-20	95982 HP00	S/CO	0.58	0.51	30.96	31.06	29.66	29.40	23.59	21.18	16.82	15.07	21.96	33.40
Monolisa anti-HCV new antigens	72306	3L003	OD/CO	0.40	0.20	0.60	0.60	0.95	1.10	5.40	4.90	7.80	7.25	7.45	0.35
Monolisa anti-HCV plus	72312	6C501.U	OD/CO	0.16	0.12	6.37	6.59	6.93	6.98	8.49	8.31	8.70	8.71	9.26	0.27
PRISM HCV	6A5248	10143 HP00	S/CO	0.23	0.15	2.73	2.93	3.06	3.29	3.50	3.50	3.35	3.66	3.78	*4
Ortho HCV 3.0 ELISA	930700	TKT116	OD/CO	0.00	0.00	5.85	6.00	6.05	8.55	≥ 9.10	7.40	≥ 9.10	8.90	≥ 9.10	0.33
Ortho HCV 3.0 SAve	940982	CG3CV738	OD/CO	0.03	0.03	6.74	6.57	7.97	7.49	≥ 9.01	≥ 9.01	≥ 9.01	≥ 9.01	≥ 9.01	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV028	OD/CO	0.05	0.00	6.79	6.80	7.56	7.52	≥ 9.09	≥ 9.09	≥ 9.09	≥ 9.09	≥ 9.09	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	GECV028	OD/CO	0.01	-0.01	4.55	4.65	≥ 5.03	≥ 5.03	≥ 5.03	≥ 5.03	≥ 5.03	≥ 5.03	≥ 5.03	0.60
Vitros ECi anti-HCV	131 8450	0100	S/CO	0.05	0.05	7.85	8.62	9.84	10.3	14.6	13.8	16.9	17.0	19.2	390.38
RIBA HCV 3.0*1	4835-900	N/A		Neg	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	
INNO-LIA HCV Ab III*1	K1028	30923701		Neg	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	
'In-house' PCR*1				Neg	POS	POS	POS	POS	Neg	Neg	Neg	POS	POS	POS	

BBI Anti-HCV seroconversion panel PHV902

Product name	Product number	Lot number	Panel ID	PHV902-01	PHV902-02	PHV902-03	PHV902-04	PHV902-05	PHV902-06	PHV902-07	Cut-off
				Days since first bleed	0	2	7	9	14	16	
Abbott HCV 3rd generation EIA	7A16-23	93292 HP00	OD/CO	0.27	0.34	0.52	1.02	4.57	6.79	7.73	0.25
Access anti-HCV	34310	590802	S/CO	0.41	0.40	0.49	0.57	2.90	5.78	10.14	42593
IMx HCV	3A99-20	95982 HP00	S/CO	0.54	0.52	1.36	3.52	13.57	14.42	13.23	32
Monolisa anti-HCV new antigens	72306	4L017.X	OD/CO	0.36	0.32	0.62	1.31	6.04	6.13	7.32	0.4
Monolisa anti-HCV plus	72312	6C501.U	OD/CO	0.11	0.10	0.89	2.57	8.06	8.46	9.20	0.26
PRISM HCV	6A5248	10143 HP00	S/CO	0.18	0.19	1.53	2.22	2.76	2.82	3.37	*4
Ortho HCV 3.0 ELISA	930700	CG3CV058	OD/CO	0.02	0.02	4.83	6.98	≥ 10.18	≥ 10.13	≥ 10.09	0.33
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	0.01	0.03	1.58	2.99	7.35	≥ 9.01	≥ 9.01	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.01	0.02	2.51	4.02	7.58	8.65	≥ 9.01	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.01	0.02	1.64	2.83	4.88	4.88	4.88	0.62
RIBA HCV 3.0* ¹				Neg	Neg	Ind	Ind	Ind	Ind	POS	
'In-house' PCR* ¹				POS	POS	POS	POS	POS	POS	POS	

BBI Anti-HCV seroconversion panel PHV903

Product name	Product number	Lot number	Panel ID	PHV903-01	PHV903-02	PHV903-03	PHV903-04	PHV903-05	PHV903-06	PHV903-07	PHV903-08	Cut-off
				Days since first bleed	0	5	7	12	14	19	21	
Abbott HCV 3rd generation EIA	7A16-23	93292 HP00	OD/CO	0.12	0.63	0.54	1.10	1.14	2.86	2.90	4.27	0.25
Access anti-HCV	34310	590802	S/CO	0.79	1.80	3.13	4.61	4.95	12.14	15.06	14.96	42593
Access HCV Ab PLUS	34330	194822	S/CO	0.05	0.17	0.38	0.88	1.13	3.55	4.90	5.92	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.40	0.45	0.83	2.03	2.31	8.37	13.23	29.59	8.9
IMx HCV	3A99-20	95982 HP00	S/CO	0.76	0.76	1.33	4.08	3.80	9.18	11.99	12.90	33.3
Monolisa anti-HCV new antigens	72306	4L017.X	OD/CO	0.48	0.58	0.73	1.20	1.45	3.45	3.89	4.75	0.4
Monolisa anti-HCV plus	72312	6C501.U	OD/CO	0.11	0.17	0.22	0.65	0.81	4.26	5.25	6.48	0.26
PRISM HCV	6A5248	10143 HP00	S/CO	0.24	0.35	0.66	0.97	1.01	2.03	2.57	3.03	*4
Ortho HCV 3.0 ELISA	930700	CG3CV058	OD/CO	0.03	0.34	0.71	1.94	1.66	4.71	7.70	8.67	0.33
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	0.02	0.04	0.09	0.45	0.50	3.44	5.15	8.01	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.02	0.11	0.34	1.14	1.36	3.44	6.10	7.29	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.02	0.17	0.60	1.61	1.55	3.77	≥ 4.88	≥ 4.88	0.62
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.19	1.57	2.28	4.73	4.61	12.9	15.5	17.1	390.38
RIBA HCV 3.0* ¹				Neg	Ind	Ind	Ind	POS	POS	POS	POS	
'In-house' PCR* ¹				POS	POS	POS	POS	POS	POS	POS	POS	

BBI Anti-HCV seroconversion panel PHV904

Product name	Product number	Lot number	Panel ID	PHV904-01	PHV904-02	PHV904-03	PHV904-04	PHV904-05	PHV904-06	PHV904-07	Cut-off
				Days since first bleed	0	2	7	9	14	21	
Abbott HCV 3rd generation EIA	7A16-23	12027 HP00	OD/CO	0.18	0.18	0.19	0.28	1.07	1.58	1.79	0.5
Access anti-HCV	34310	590803	S/CO	0.36	0.37	0.36	0.42	0.63	1.62	2.11	38489
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.03	0.21	0.89	2.24	3.47	3.87	2979761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.24	0.14	0.91	2.26	11.13	18.13	26.58	8.9
IMx HCV	3A99-20	12220 HP00	S/CO	0.47	0.50	0.51	0.53	4.51	4.33	4.05	22.6
Monolisa anti-HCV new antigens	72307	5G522.X	OD/CO	0.29	0.14	0.21	0.49	5.15	7.90	7.56	0.31
Monolisa anti-HCV plus	72312	6C501.U	OD/CO	0.07	0.08	0.33	1.24	3.31	5.20	6.65	0.26
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.15	0.20	0.44	1.64	4.81	6.86	5.92	0.23
Monolisa anti-HCV plus Version 2	72318	9M512T	OD/CO	0.14	0.19	0.44	0.81	2.22	5.06	6.87	0.23
PRISM HCV	6A5248	10143 HP00	S/CO	0.10	0.10	0.38	1.05	2.14	2.43	*3	*4
Ortho HCV 3.0 ELISA	930700	CG3CV288	OD/CO	0.02	0.02	0.23	1.98	5.33	5.29	7.61	0.39
Ortho HCV 3.0 SAve	940982	CG3CV738	OD/CO	0.01	0.01	0.05	0.37	2.42	4.23	5.56	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV028	OD/CO	0.02	0.02	0.26	1.47	4.19	6.38	6.78	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	GECV028	OD/CO	0.00	0.00	0.25	1.38	3.46	4.42	4.63	0.62
Vitros Eci anti-HCV	131 8450	0100	OD/CO	0.05	0.07	0.75	2.78	7.35	9.71	10.6	390.38
RIBA HCV 3.0 ^{*1}	930780	MKD513		Neg	Neg	Neg	Neg	Ind	Ind	Ind	
INNO-LIA HCV Ab III ^{*1}	K-1028	50915224		Neg	Neg	Neg	Neg	Ind	Ind	Ind	
AMPLICOR HCV monitor test ^{*1}	87382	82075	copies/ml	6 x 10 ⁵	1 x 10 ⁵	2 x 10 ⁵	2 x 10 ⁵	2 x 10 ⁴	3 x 10 ⁴	1 x 10 ⁵	

BBI anti-HCV seroconversion panel PHV905 (genotype 1A)

Product name	Product number	Lot number	Panel ID Days since first bleed	PHV905-01	PHV905-02	PHV905-03	PHV905-04	PHV905-05	PHV905-06	PHV905-07	PHV905-08	PHV905-09	Cut-off
				0	4	7	11	14	18	21	25	28	
Abbott HCV 3rd generation EIA	7A16-23	16084 HP00	OD/CO	0.28	0.26	0.28	0.26	0.33	0.38	0.52	2.89	4.38	0.23
Access anti-HCV	34310	690810	S/CO	0.24	0.25	0.27	0.32	0.37	0.40	0.80	9.62	14.53	47186
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.03	0.09	0.37	0.63	0.81	1.94	5.56	6.39	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.17	0.14	0.23	0.84	1.33	2.44	5.27	29.08	46.18	8.9
IMx HCV	3A99-20	16534 HP00	S/CO	0.46	0.50	0.56	0.56	0.57	0.63	0.87	2.19	2.51	26.2
Monolisa anti-HCV new antigens	72307	B5L524.X	OD/CO	0.11	0.11	0.12	0.22	0.20	0.37	2.08	6.24	5.92	0.35
Monolisa anti-HCV plus	72311	6C501.U	OD/CO	0.04	0.04	0.07	0.35	0.66	1.43	2.99	6.04	6.31	0.27
Ortho HCV 3.0 SAve	940982	CG3CV388	OD/CO	0.02	0.02	0.05	0.39	0.85	1.91	3.26	6.37	8.11	0.34
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	CEGV028	OD/CO	0.02	0.03	0.04	0.83	1.37	2.39	3.77	7.18	8.41	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	CEGV028	OD/CO	0.01	0.01	0.01	0.39	0.42	1.58	2.69	≥ 4.98	≥ 4.98	0.6
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.04	0.04	0.07	0.50	1.44	2.31	6.81	15.5	16.7	390.38
RIBA HCV 3.0 * ¹	930780	MKL603		Neg	Neg	Neg	Ind	Ind	Ind	POS	POS	POS	
INNO-LIA HCV Ab III * ¹	K-1028	60318428		Neg	Neg	Neg	Neg	Neg	Neg	Ind	POS	POS	
AMPLICOR HCV monitor test * ¹	87382	82105	copies/ml	4 x 10 ⁵	5 x 10 ⁵	4 x 10 ⁵	8 x 10 ⁴	3 x 10 ⁵	3 x 10 ⁵	2 x 10 ⁵	7 x 10 ⁴	2 x 10 ⁴	

BBI Anti-HCV seroconversion panel PHV906 (genotype 1B)

Product name	Product number	Lot number	Panel ID	PHV906-01	PHV906-02	PHV906-03	PHV906-04	PHV906-05	PHV906-06	PHV906-07	Cut-off
			Days since first bleed	0	2	7	10	14	17	21	
Abbott HCV 3rd generation EIA	7A16-23	16084 HP00	OD/CO	0.35	0.55	0.96	1.32	2.10	2.88	3.24	0.23
Access anti-HCV	34310	690810	S/CO	0.35	0.47	1.02	1.97	5.02	9.55	17.72	47186
Access HCV Ab PLUS	34330	194822	S/CO	3.24	1.13	5.23	5.52	6.46	6.87	7.19	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	14.52	21.34	32.82	38.30	44.97	47.36	54.35	8.9
IMx HCV	3A99-20	16534 HP00	S/CO	0.75	0.87	1.23	1.42	1.83	1.98	2.59	27.4
Monolisa anti-HCV new antigens	72307	B5L524.X	OD/CO	0.40	0.55	2.30	3.19	6.05	7.19	7.51	0.35
Monolisa anti-HCV plus	72311	6C001.U	OD/CO	1.98	3.89	6.00	6.58	6.96	8.80	7.99	0.26
Ortho HCV 3.0 SAve	940982	CG3CV388	OD/CO	4.39	4.64	5.38	6.57	≥10.00	≥10.00	8.91	0.34
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV028	OD/CO	3.41	4.83	6.02	6.97	7.48	8.10	8.05	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	GECV028	OD/CO	2.47	3.44	4.48	≥ 4.98	≥ 4.98	≥ 4.98	≥ 4.98	0.6
Vitros Eci anti-HCV	131 8450	0100	S/CO	5.51	6.31	6.01	9.02	11.0	12.5	13.0	390.38
RIBA HCV 3.0 * ¹	930780	MKL603		Ind	Ind	POS	POS	POS	POS	POS	
INNO-LIA HCV Ab III * ¹	K-1028	60318428		Ind	Ind	Ind	Ind	POS	POS	POS	
AMPLICOR HCV monitor test * ¹	87382	82105	copies/ml	2 x 10 ⁶	1 x 10 ⁶	1 x 10 ⁶	4 x 10 ⁶	1 x 10 ⁶	2 x 10 ⁶	1 x 10 ⁶	

BBI Anti-HCV seroconversion panel PHV907 (genotype 1b)

Product name	Product number	Lot number	Panel ID	PHV907-01	PHV907-02	PHV907-03	PHV907-04	PHV907-05	PHV907-06	PHV907-07	Cut-off
			Days since first bleed	0	4	7	13	18	21	164	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.12	0.13	0.13	0.27	0.77	1.23	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.02	0.02	1.27	3.29	3.95	9.55	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.21	0.23	0.29	0.50	3.16	8.70	49.52	8.9
IMx HCV	3A99-20	22210 HP01	S/CO	0.74	0.63	0.51	0.55	0.63	0.59	16.20	22.4
Monolisa anti-HCV new antigens	72307	B6F529.X	OD/CO	0.07	0.04	0.07	0.38	1.92	1.89	7.91	0.29
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.05	0.08	0.04	0.15	0.88	1.29	7.83	0.28
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.12	0.12	0.10	0.43	1.33	1.88	9.99	0.23
Ortho HCV 3.0 SAve	940982	CG3CV628	OD/CO	0.02	0.01	0.01	0.35	1.62	2.58	8.36	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV038	OD/CO	0.07	0.07	0.07	0.27	1.75	2.90	8.19	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	GECV038	OD/CO	0.04	0.03	0.02	0.08	0.65	1.30	4.87	0.62
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.05	0.05	0.05	1.83	6.68	8.90	22.80	402.56
RIBA HCV 3.0 * ¹	930780	MLB603		Neg	Neg	Neg	Ind	Ind	POS	N/K	
AMPLICOR HCV monitor test * ¹	87382	82136	copies/ml	3 x 10 ⁶	2 x 10 ⁶	1 x 10 ⁶	1 x 10 ⁶	1 x 10 ⁶	1 x 10 ⁶	N/K	

BBI anti-HCV seroconversion panel PHM908

Product name	Product number	Lot number	Panel ID	PHV908-01	PHV908-02	PHV908-03	PHV908-04	PHV908-05	PHV908-06	PHV908-07	PHV908-08	PHV908-09	PHV908-10	PHV908-11	PHV908-12	PHV908-13	Cut-off
			Days since first bleed	0	3	5	11	13	19	25	27	32	35	41	45	48	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.13	0.13	0.14	0.14	0.17	0.17	0.41	0.72	1.83	2.56	3.84	4.42	3.52	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.02	0.04	0.39	0.61	1.93	3.99	4.54	5.40	5.68	6.14	5.90	5.97	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.15	0.17	0.22	1.44	2.35	7.42	22.03	32.98	48.61	59.07	55.19	55.66	56.30	8.9
IMx HCV	3A99-20	22210 HP01	S/CO	0.46	0.54	0.46	0.50	0.47	0.54	0.51	0.63	0.66	0.78	1.40	1.91	2.23	22.6
Monolisa anti-HCV new antigens	72307	B6E528.X	OD/CO	0.03	0.02	0.04	0.04	0.04	0.09	0.51	0.74	2.03	2.80	4.25	4.98	4.74	0.34
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.05	0.04	0.06	0.11	0.17	0.84	4.50	5.57	7.31	7.42	8.05	8.48	8.57	0.28
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.10	0.08	0.09	0.20	0.41	0.37	4.95	5.25	6.31	6.67	6.94	6.24	6.78	0.23
Ortho HCV 3.0 SAvE	940982	CG3CV628	OD/CO	-0.03	0.00	-0.03	0.33	0.66	2.28	4.81	5.87	7.20	7.55	7.45	8.20	8.43	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV038	OD/CO	0.06	0.05	0.06	0.62	0.73	2.19	3.82	4.69	5.80	6.34	7.16	7.21	7.02	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV038	OD/CO	0.03	0.03	0.04	0.32	0.32	1.17	2.43	3.00	3.88	4.30	4.87	4.87	4.87	0.62
Vitros ECI anti-HCV	131 8450	0100	OD/CO	0.06	0.05	0.06	0.65	1.30	2.43	5.04	5.74	7.97	7.83	10.2	11.2	10.6	390.38
RIBA HCV 3.0 *1	930780	MLE398		Neg	Neg	Neg	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	
AMPLICOR HCV monitor test *1	87382	82246	copies/ml	2 x 10 ⁵	3 x 10 ⁵	3 x 10 ⁵	1 x 10 ⁵	2 x 10 ⁵	1 x 10 ⁵	5 x 10 ⁴	8 x 10 ⁴	1 x 10 ⁵	2 x 10 ⁴	1 x 10 ⁴	2 x 10 ⁴	2 x 10 ⁵	

Anti-HCV seroconversion panel PHV909 (genotype 3)

Product name	Product number	Lot number	Panel ID	PHV909-01	PHV909-02	PHV909-03	Cut-off
			Days since first bleed	0	28	30	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.40	2.29	2.58	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.41	4.65	4.45	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.18	0.66	0.86	8.9
IMx HCV	3A99-20	22210 HP00	S/CO	0.40	0.38	0.40	25.2
Monolisa anti-HCV new antigens	72307	B6F529.X	OD/CO	0.55	7.24	6.91	0.26
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.12	2.42	2.43	0.28
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	0.03	3.04	2.61	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV038	OD/CO	0.12	2.93	2.87	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV038	OD/CO	0.02	0.73	0.73	0.62
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.42	11.3	11.5	390.38
RIBA HCV 3.0 * ¹	930780	N/A		Neg	Ind	Ind	
AMPLICOR HCV monitor test * ¹	87382	82246	copies/ml	1 x 10 ⁴	4 x 10 ⁴	2 x 10 ⁴	

Anti-HCV seroconversion panel PHV910 (genotype 1b)

Product name	Product number	Lot number	Panel ID	PHV910-01	PHV910-02	PHV910-03	PHV910-04	PHV910-05	Cut-off
			Days since first bleed	0	4	8	11	15	
Abbott HCV 3rd generation EIA	7A16-23	4309HP00	OD/CO	0.12	0.22	1.78	3.66	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.05	0.26	3.30	5.57	7.00	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.16	0.26	2.73	11.09	23.33	8.9
IMx HCV	3A99-20	27252 HP00	S/CO	0.67	0.52	0.67	1.16	1.28	25.8
Monolisa anti-HCV new antigens	72307	6K533P	OD/CO	0.15	0.11	1.42	2.20	2.54	0.33
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.21	0.40	0.47	2.19	3.12	0.23
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.23	0.20	1.39	2.74	4.31	0.23
Ortho HCV 3.0 SAvE	940982	CG3CV778	OD/CO	0.02	0.21	3.52	6.33	7.08	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV398	OD/CO	0.02	0.08	2.97	4.79	6.13	0.35
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.16	0.57	7.04	12.9	15.0	390.38
RIBA HCV 3.0 * ¹	930780	MLE398		Neg	Neg	POS	POS	POS	
AMPLICOR HCV monitor test * ¹	87382	82256	copies/ml	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	

BBI Anti-HCV seroconversion panel PHV911 (genotype 1a)

Product name	Product number	Lot number	Panel ID	PHV911-01	PHV911-02	PHV911-03	PHV911-04	PHV911-05	Cut-off
			Days since first bleed	0	3	14	21	24	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.16	0.17	1.11	4.95	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.04	1.40	5.97	6.52	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.20	0.21	3.00	31.75	49.07	8.9
IMx HCV	3A99-20	27252 HP00	S/CO	0.54	0.55	0.60	2.15	2.70	25.8
Monolisa anti-HCV new antigens	72307	6K533P	OD/CO	0.14	0.15	1.06	5.78	6.53	0.34
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.04	0.05	1.04	6.94	8.94	0.21
Ortho HCV 3.0 SAve	940982	CG3CV778	OD/CO	0.00	0.01	3.06	≥10.19	≥10.19	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV398	OD/CO	0.03	0.03	1.51	6.87	7.20	0.35
Vitros <i>ECi</i> anti-HCV	131 8450	0100	S/CO	0.05	0.06	6.48	16.40	17.10	402.56
RIBA HCV 3.0 * ¹	930780	MLE398		Neg	Neg	POS	POS	POS	
AMPLICOR HCV monitor test * ¹	87382	82256	copies/ml	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	

BBI Anti-HCV seroconversion panel PHV912 (genotype 2b/3)

Product name	Product number	Lot number	Panel ID	PHV912-01	PHV912-02	PHV912-03	Cut-off
			Days since first bleed	0	4	7	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.44	0.41	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.22	0.22	8.78	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.51	0.60	12.58	8.9
IMx HCV	3A99-20	27252 HP00	S/CO	1.39	1.32	11.34	25.8
Monolisa anti-HCV new antigens	72307	6K533P	OD/CO	0.49	0.54	6.67	0.34
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.30	0.28	8.05	0.28
Ortho HCV 3.0 SAve	940982	CG3CV778	OD/CO	0.05	0.10	≥10.14	0.33
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV398	OD/CO	0.17	0.12	9.71	0.35
Vitros <i>ECi</i> anti-HCV	131 8450	0100	S/CO	0.25	0.25	25.2	390.38
RIBA HCV 3.0 * ¹	930780	MLE398		Neg	Neg	Ind	
AMPLICOR HCV monitor test * ¹	87382	82256	copies/ml	4 x 10 ⁴	>5 x 10 ⁵	4 x 10 ⁴	

BBI Anti-HCV seroconversion panel PHV913 (genotype 2b)

Product name	Product number	Lot number	Panel ID	PHV913-01	PHV913-02	PHV913-03	PHV913-04	Cut-off
			Days since first bleed	0	2	7	9	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.16	0.23	1.28	1.21	0.37
Access HCV Ab PLUS	34330	194822	S/CO	0.10	0.65	3.65	3.43	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.19	0.22	0.41	0.60	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.12	0.10	0.14	0.18	23.6
Monolisa anti-HCV new antigens	72307	7F536P	OD/CO	0.59	0.91	4.77	4.54	0.29
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.10	0.34	2.99	2.90	0.28
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	CEGV118	OD/CO	0.04	0.12	1.50	1.69	0.34
Vitros <i>ECi</i> anti-HCV	131 8450	0100	S/CO	0.09	1.13	7.76	8.08	390.38
RIBA HCV 3.0 *1	MMB252	930780		Neg	Neg	Ind	Ind	
AMPLICOR HCV monitor test *1	82047	87382	copies/ml	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	

BBI Anti-HCV seroconversion panel PHV914 (genotype 2b)

Product name	Product number	Lot number	Panel ID	PHV914-01	PHV914-02	PHV914-03	PHV914-04	PHV914-05	PHV914-06	PHV914-07	PHV914-08	PHV914-09	Cut-off
			Days since first bleed	0	5	9	12	16	19	24	30	33	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.08	0.09	0.10	0.09	0.54	1.29	4.26	5.93	5.93	0.34
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.02	0.03	0.16	2.18	3.08	5.41	6.53	7.11	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.19	0.16	0.19	0.63	1.37	1.76	5.42	18.90	22.57	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.15	0.08	0.11	0.14	0.29	0.45	3.27	10.68	11.36	22.5
Monolisa anti-HCV new antigens	72307	7F536P	OD/CO	0.19	0.13	0.16	0.31	1.41	2.51	4.96	5.44	5.65	0.29
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.03	0.04	0.04	0.08	0.75	1.56	4.48	5.40	5.30	0.28
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV118	OD/CO	0.01	0.02	0.03	0.06	1.16	2.05	4.50	6.84	7.63	0.34
Vitros <i>ECi</i> anti-HCV	131 8450	0100	S/CO	0.05	0.06	0.07	0.23	5.88	8.7	14.2	18.6	19.5	390.38
RIBA HCV 3.0 *1	MMB252	930780		Neg	Neg	Neg	Neg	Ind	Ind	Ind	POS	POS	
AMPLICOR HCV monitor test *1	82047	87382	copies/ml	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	

Anti-HCV seroconversion panel PHV915 (genotype 2b)

Product name	Product number	Lot number	Panel ID	PHV915-01	PHV915-02	PHV915-03	PHV915-04	Cut-off
			Days since first bleed	0	5	12	14	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.23	0.22	0.33	0.40	0.38
Access HCV Ab PLUS	34330	194822	S/CO	0.09	0.28	0.65	0.97	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.44	1.50	4.19	9.16	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.29	0.47	1.32	3.22	22.5
Monolisa anti-HCV new antigens	72307	7F536P	OD/CO	0.26	0.64	1.26	2.27	0.38
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.14	0.47	0.86	1.44	0.28
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV118	OD/CO	0.03	0.24	0.85	2.21	0.34
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.11	0.67	2.32	4.71	390.38
RIBA HCV 3.0 *1	MMB252	930780		Neg	Ind	Ind	Ind	
AMPLICOR HCV monitor test *1	82047	87382	copies/ml	1 x 10 ⁴	1 x 10 ³	2 x 10 ⁴	2 x 10 ⁴	

Anti-HCV seroconversion panel PHV916 (genotype 2b)

Product name	Product number	Lot number	Panel ID	PHV916-01	PHV916-02	PHV916-03	PHV916-04	PHV916-05	PHV916-06	PHV916-07	PHV916-08	Cut-off
			Days since first bleed	0	2	7	9	16	19	23	28	
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.04	0.04	0.04	0.17	0.58	1.83	2.89	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.25	0.21	0.19	0.23	1.57	5.33	14.59	21.53	8.9
Monolisa anti-HCV plus	72311	8G525Q	OD/CO	0.08	0.09	0.12	0.11	0.10	0.27	1.22	2.18	0.28
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV428	OD/CO	0.02	0.02	0.02	0.01	0.11	0.87	2.79	3.13	0.34
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.05	0.05	0.05	0.04	0.38	1.44	4.32	5.39	402.56
RIBA HCV 3.0 *1	MMB252	930780		Neg	Neg	Neg	Neg	Neg	Neg	POS	POS	
AMPLICOR HCV monitor test *1	82047	87382	copies/ml	3 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	4 x 10 ⁵	2 x 10 ⁵	

BBI anti-HCV seroconversion panel PHM917

Product name	Product number	Lot number	Panel ID	PHV917-01	PHV917-02	PHV917-03	PHV917-04	PHV917-05	PHV917-06	PHV917-07	PHV917-08	PHV917-09	PHV917-10	Cut-off
			Days since first bleed	0	13	20	22	85	131	135	138	146	152	
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.04	0.03	0.03	5.89	5.33	5.67	6.70	8.41	8.44	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.20	0.29	0.28	0.26	38.09	24.94	29.18	34.47	55.85	59.41	8.9
Vitros ECI anti-HCV	131 8450	0100	OD/CO	0.05	0.05	0.05	0.05	11.3	10.9	11.9	12.0	15.8	15.9	402.56
RIBA HCV 3.0 *1	MMB252	930780		Neg	Neg	Neg	Neg	POS	POS	POS	POS	POS	POS	
AMPLICOR HCV monitor test *1	82047	87382	copies/ml	BLD	>5 x 10 ⁵	>5 x 10 ⁵	>5 x 10 ⁵	BQR	BQR	3 x 10 ³	BLD	BLD	BQR	

BCP anti-HCV seroconversion panel SD976

Product name	Product number	Lot number	Panel ID	SD976-01	SD976-02	SD976-03	SD976-04	SD976-05	SD976-06	SD976-07	SD976-08	SD976-09	SD976-10	SD976-11	SD976-12	SD976-13	SD976-14	SD976-15	SD976-16	SD976-17	SD976-18	SD976-19	SD976-20	Cut-off
			Days since first bleed	0	58	71	154	164	225	229	238	310	313	319	376	380	383	454	458	462	524	526	531	
Abbott HCV 3rd generation EIA	7A16-23	12027 HP00	OD/CO	0.17	0.18	0.14	0.19	0.14	0.17	0.15	0.15	0.17	0.12	0.17	0.16	0.16	0.09	1.44	2.62	>3.99	>3.99	>3.99	>3.99	0.5
Access anti-HCV	34310	194822	S/CO	0.53	0.32	0.30	0.32	0.35	0.31	0.30	0.28	0.34	0.33	0.29	0.32	0.33	0.31	3.82	6.80	14.74	71.05	80.67	76.79	38489
IMx HCV	3A99-20	12220 HP00	S/CO	0.58	0.62	1.35	1.03	1.44	0.82	0.82	0.78	0.56	0.61	0.91	1.35	0.80	0.62	0.76	0.75	1.58	28.94	32.52	33.16	21.1
Monolisa anti-HCV new antigens	72307	5B518.X	OD/CO	0.12	0.19	0.08	0.13	0.16	0.12	0.14	0.14	0.13	0.12	0.12	0.10	0.13	0.10	2.26	2.68	6.09	12.41	11.39	11.31	0.19
Monolisa anti-HCV plus	72312	6C501.U	OD/CO	0.08	0.07	0.08	0.05	0.07	0.06	0.07	0.07	0.10	0.07	0.08	0.06	0.07	0.06	2.20	2.15	4.21	8.10	8.32	7.84	0.26
PRISM HCV	6A5248	10143 HP00	S/CO	0.13	0.14	0.19	0.34	0.16	0.14	Insuff	0.12	0.15	0.21	0.19	0.31	0.20	0.22	1.00	1.64	2.20	4.39	4.48	4.18	*4
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	0.04	0.02	0.03	NT	0.01	0.02	0.04	0.03	0.03	0.01	0.03	0.02	0.01	0.03	0.73	0.88	2.72	8.90	8.90	8.90	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.01	0.01	0.03	0.02	0.02	0.05	Insuff	0.04	0.00	0.00	0.02	0.02	0.02	0.02	2.55	3.34	6.67	9.09	9.00	9.00	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (long incubation)	9307401	GECV028	OD/CO	0.00	0.02	0.02	-0.01	0.00	0.05	Insuff	0.01	0.00	-0.01	-0.01	0.01	0.00	0.00	0.31	0.74	2.36	5.03	5.03	5.03	0.6
RIBA HCV 3.0*2	930780	NK		Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Ind	Ind	Ind	POS	POS	POS	

BCP anti-HCV seroconversion panel 6211

Product name	Product number	Lot number	Panel ID	6211-31	6211-32	6211-33	6211-34	6211-35	6211-36	6211-37	6211-38	6211-39	6211-40	Cut-off	
			Days since first bleed	150	154	157	161	164	168	171	182	186	189		
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.14	0.15	0.13	0.13	0.13	0.14	0.13	0.24	1.50	4.76	0.4	
Access HCV Ab PLUS	34330	194822	S/CO	0.05	0.05	0.05	0.05	0.05	0.05	0.06	0.83	1.95	3.18	2978761	
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.14	0.16	0.12	0.17	0.14	0.16	0.14	3.66	20.41	38.39	8.9	
IMx HCV	3A99-20	22210 HP01	S/CO	0.38	0.43	0.56	0.46	0.47	0.46	0.43	0.55	0.80	0.88	22.4	
Monolisa anti-HCV new antigens	72307	B5M525	OD/CO	0.09	0.00	0.09	0.04	0.09	0.06	0.04	0.10	0.10	0.62	0.37	
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.08	0.07	0.04	0.05	0.06	0.02	0.02	0.72	2.53	4.08	0.21	
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.11	0.08	0.09	0.11	0.07	0.07	0.12	0.97	2.44	2.94	0.23	
Ortho HCV 3.0 SAvE	940982	CG3CV448	OD/CO	0.01	0.02	0.00	0.00	0.00	0.01	0.01	0.83	5.29	6.84	0.33	
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.02	0.01	0.02	0.03	0.03	0.03	0.01	1.54	4.61	5.37	0.33	
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.01	0.02	0.01	0.01	0.02	0.01	0.00	1.19	3.26	4.30	0.6	
Vitros ECi anti-HCV	131 8450	0100	S/CO	0.08	0.07	0.08	0.06	0.06	0.07	0.06	2.00	6.18	8.96	390.38	
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	Neg	Ind	POS	POS		
'In-house' HCV PCR *2	NA	NA	copies/ml	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	
Chiron bDNA *2	NA	NA	copies/ml	4 x 10 ⁷	1 x 10 ⁸	> 1 x 10 ⁸	> 1 x 10 ⁸	> 1 x 10 ⁸	> 1 x 10 ⁸	> 1 x 10 ⁸	> 1 x 10 ⁸	1 x 10 ⁸	> 1 x 10 ⁸		

BCP anti-HCV seroconversion panel 6212

Product name	Product number	Lot number	Panel ID	6212-01	6212-02	6212-03	6212-04	6212-05	6212-06	6212-07	6212-08	6212-09	Cut-off
				Days since first bleed	0	12	14	23	26	32	37	53	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.09	0.11	0.10	0.31	0.40	0.80	0.69	4.94	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.40	0.74	3.81	5.07	4.84	4.59	6.77	7.12	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.15	3.49	6.09	21.11	23.62	21.51	20.88	39.87	42.14	8.9
IMx HCV	3A99-20	19191 HP00	S/CO	0.52	3.01	3.34	5.93	5.61	5.15	4.83	7.85	7.70	26.4
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.03	0.01	0.04	0.10	0.27	1.18	1.93	8.86	10.99	0.31
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.05	0.07	0.08	0.36	0.53	1.29	1.48	7.00	7.45	0.23
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.07	0.18	0.10	0.41	0.72	1.38	1.96	8.60	8.68	0.23
PRISM HCV *2	6A5248	NA	S/CO	0.08	1.26	1.11	2.65	3.13	3.07	2.80	3.48	4.04	NA
Ortho HCV 3.0 SAVe	940982	CG3CV528	OD/CO	0.01	0.85	1.15	4.08	5.04	5.51	5.43	≥13.37	≥13.37	0.34
Ortho HCV 3.0 ELISA / enhanced SAVe (short incubation)	9307401	CEGV028	OD/CO	0.02	1.08	1.49	4.12	4.80	5.03	4.75	8.62	≥ 9.01	0.33
Ortho HCV 3.0 ELISA / enhanced SAVe (standard incubation)	9307401	CEGV028	OD/CO	0.01	0.53	0.83	3.18	3.62	3.79	4.30	≥ 4.98	≥ 4.98	0.6
Vitros ECi anti-HCV	131 8450	0100	S/CO	0.04	1.19	1.68	4.98	6.11	6.49	7.01	14.9	15.4	390.38
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Ind	Ind	Ind	Ind	Ind	Ind	
In-house' HCV PCR *2	NA	NA	copies/ml	8 x 10 ⁵	2 x 10 ⁵	9 x 10 ⁴	1 x 10 ⁵	5 x 10 ⁴	8 x 10 ⁴	8 x 10 ⁴	2 x 10 ⁵	4 x 10 ⁵	
Chiron bDNA *2	NA	NA	copies/ml	2 x 10 ⁶	2 x 10 ⁵	< 2 x 10 ⁵	2 x 10 ⁵	2 x 10 ⁵	< 2 x 10 ⁵	4 x 10 ⁵	5 x 10 ⁵	4 x 10 ⁵	

BCP anti-HCV seroconversion panel 6213

Product name	Product number	Lot number	Panel ID	6213-01	6213-02	6213-03	6213-04	6213-05	6213-06	6213-07	6213-08	6213-09	6213-10	6213-11	6213-12	Cut-off
				0	2	8	11	15	18	28	30	35	37	43	46	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.29	0.33	0.32	0.27	0.34	0.34	0.31	0.30	0.31	0.47	1.64	2.08	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.03	0.03	0.04	0.03	0.03	0.03	0.03	0.05	0.42	4.26	4.69	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.86	0.79	0.85	0.91	0.76	0.91	0.92	0.88	0.96	2.54	32.52	34.12	8.9
IMx HCV	3A99-20	19191 HP00	S/CO	0.53	0.49	0.49	0.51	0.47	0.45	0.48	0.47	0.44	0.76	7.77	7.34	23.4
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.05	0.04	0.04	0.04	0.05	0.04	0.05	0.04	0.06	0.15	3.48	5.04	0.32
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.07	0.04	0.03	0.03	0.04	0.06	0.07	0.08	0.09	0.26	3.85	3.79	0.23
PRISM HCV *2	6A5248	NA	S/CO	0.06	0.05	0.06	0.06	0.06	0.06	0.05	0.05	0.08	0.57	2.69	2.95	NA
Ortho HCV 3.0 SAVE	940982	CG3CV528	OD/CO	0.05	0.04	0.05	0.07	0.06	0.05	0.04	0.03	0.07	1.26	≥ 10.38	≥ 10.34	0.34
Ortho HCV 3.0 ELISA / enhanced SAVE (short incubation)	9307401	GECV028	OD/CO	0.03	0.03	0.03	0.03	0.02	0.03	0.02	0.02	0.02	0.60	6.04	7.29	0.33
Ortho HCV 3.0 ELISA / enhanced SAVE (standard incubation)	9307401	GECV028	OD/CO	0.03	0.01	0.01	0.01	0.00	0.01	0.00	0.01	0.01	0.58	4.76	≥ 4.98	0.6
Vitros ECi anti-HCV	131 8450	0100	S/CO	0.08	0.08	0.09	0.09	0.09	0.07	0.09	0.08	0.15	2.54	15.1	16.0	39.38
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	POS	POS	
'In-house' HCV PCR *2	NA	NA	copies/ml	< 1 x 10 ²	< 1 x 10 ²	< 1 x 10 ²	1 x 10 ⁵	4 x 10 ⁵	3 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	2 x 10 ⁶	2 x 10 ⁶	4 x 10 ⁶	5 x 10 ⁶	
Chiron bDNA *2	NA	NA	copies/ml	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	3 x 10 ⁵	7 x 10 ⁵	2 x 10 ⁶	2 x 10 ⁷	1 x 10 ⁷	1 x 10 ⁷	3 x 10 ⁷	2 x 10 ⁷	1 x 10 ⁷	

BCP anti-HCV seroconversion panel 6214

Product name	Product number	Lot number	Panel ID	6214-01	6214-02	6214-03	6214-04	6214-05	6214-06	6214-07	6214-08	6214-09	6214-10	6214-11	6214-12	6214-13	Cut-off
			Days since first bleed	0	2	8	10	16	18	23	25	30	32	49	53	56	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.20	0.18	0.19	0.25	0.17	0.14	0.17	0.19	0.25	0.31	3.52	4.83	4.95	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.02	0.02	0.02	0.02	0.02	0.05	0.14	1.00	1.95	6.31	6.46	6.28	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.25	0.20	0.20	0.15	0.17	0.23	0.90	2.77	18.97	19.43	71.97	73.93	72.96	8.9
IMx HCV	3A99-20	19191 HP00	S/CO	0.47	0.51	0.48	0.45	0.47	0.50	0.49	0.51	0.56	0.72	2.17	2.47	2.67	23.2
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.05	0.04	0.03	0.02	0.04	0.04	0.04	0.02	0.07	0.09	4.09	3.84	4.16	0.32
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.05	0.06	0.04	0.07	0.07	0.02	0.03	0.05	0.28	1.13	7.05	7.77	8.22	0.23
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	0.11	0.10	0.08	0.09	0.04	0.09	0.06	0.12	0.87	1.98	8.66	7.66	6.95	0.23
PRISM HCV ⁺²	6A5248	NA	S/CO	0.06	0.05	0.05	0.06	0.06	0.07	0.27	0.64	1.07	1.60	3.14	3.45	3.32	NA
Ortho HCV 3.0 SAvE	940982	CG3CV528	OD/CO	0.01	0.02	0.01	0.01	0.01	0.01	0.02	0.13	2.20	5.09	≥10.39	≥13.369	≥13.369	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.01	0.02	0.00	0.02	0.02	0.02	0.03	0.08	1.23	3.02	7.47	7.94	7.75	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.00	0.01	-0.01	0.00	0.01	0.01	0.01	0.02	1.05	3.07	≥ 4.98	≥ 4.98	≥ 4.98	0.60
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.06	0.09	0.06	0.07	0.06	0.06	0.06	0.11	1.92	4.62	12.1	12.1	12.3	390.38
RIBA HCV 3.0 ⁺²	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Ind	Ind	POS	POS	POS	
'In-house' HCV PCR ⁺²	NA	NA	copies/ml	2 X 10 ⁶	> 5 X 10 ⁶	> 5 X 10 ⁶	2 X 10 ⁶	5 X 10 ⁶	2 X 10 ⁶	> 5 X 10 ⁶	> 5 X 10 ⁶	> 5 X 10 ⁶	3 X 10 ⁶	1 X 10 ⁶	1 X 10 ⁶	8 X 10 ⁵	
Chiron bDNA ⁺²	NA	NA	copies/ml	6 X 10 ⁶	7 X 10 ⁶	9 X 10 ⁶	7 X 10 ⁶	6 X 10 ⁶	3 X 10 ⁶	5 X 10 ⁶	1 X 10 ⁷	9 X 10 ⁶	6 X 10 ⁶	2 X 10 ⁶	3 X 10 ⁶	2 X 10 ⁶	

BCP anti-HCV seroconversion panel 6215

Product name	Product number	Lot number	Panel ID	6215-01	6215-02	6215-03	6215-04	Cut-off
			Days since first bleed	0	3	10	20	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.11	0.10	0.14	2.61	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.02	0.10	3.24	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.15	0.18	0.19	3.62	8.9
IMx HCV	3A99-20	19191 HP00	S/CO	0.44	0.44	0.57	1.83	23.6
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.03	0.03	0.03	3.70	0.32
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.04	0.05	0.05	1.90	0.21
PRISM HCV *2	6A5248	N/A	S/CO	0.04	0.04	0.15	1.47	NA
Ortho HCV 3.0 SAvE	940982	CG3CV528	OD/CO	0.00	0.01	0.02	4.66	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.03	0.04	0.03	3.24	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.01	0.02	0.01	2.10	0.6
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.05	0.04	0.10	11.5	390.38
RIBA HCV 3.0 *2	N/A	N/A		Neg	Neg	Neg	Ind	
'In-house' HCV PCR *2	N/A	N/A	copies/ml	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	> 5 x 10 ⁶	
Chiron bDNA *2	N/A	N/A	copies/ml	> 1 x 10 ⁸	1 x 10 ⁸	6 x 10 ⁷	5 x 10 ⁷	

BCP anti-HCV seroconversion panel 6216

Product name	Product number	Lot number	Panel ID	6216-01	6216-02	6216-03	6216-04	6216-05	6216-06	6216-07	Cut-off
			Days since first bleed	0	3	8	10	15	17	23	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.27	0.29	0.25	0.26	0.31	0.31	3.63	0.4
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.03	0.04	0.03	0.03	0.04	2.62	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.38	0.40	0.48	0.25	0.36	0.27	1.50	8.9
IMx HCV	3A99-20	19191 HP00	S/CO	0.51	0.50	0.46	0.46	0.48	0.46	0.56	23.6
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.08	0.09	0.06	0.04	0.08	0.07	0.15	0.31
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.08	0.09	0.06	0.04	0.06	0.06	0.49	0.23
PRISM HCV *2	6A5248	NA	S/CO	0.07	0.07	0.06	0.06	0.07	0.07	1.13	NA
Ortho HCV 3.0 SAvE	940982	CG3CV528	OD/CO	0.04	0.05	0.05	0.04	0.05	0.04	3.53	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.02	0.02	0.03	0.07	0.05	0.03	2.37	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.00	0.01	0.01	0.02	0.01	0.01	2.44	0.6
Vitros ECI anti-HCV	131 8450	0100	S/CO	0.11	0.11	0.07	0.11	0.17	0.10	9.93	390.38
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	Ind	
'In-house' HCV PCR *2	NA	NA	copies/ml	< 1 x 10 ²	< 1 x 10 ²	< 1 x 10 ²	< 1 x 10 ²	< 1 x 10 ²	< 1 x 10 ²	5 x 10 ²	
Chiron bDNA *2	NA	NA	copies/ml	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	< 2 x 10 ⁵	

BCP anti-HCV 'false positive' seroconversion panel 6217

Product name	Product number	Lot number	Panel ID	6217-01	6217-02	6217-03	6217-04	6217-05	Cut-off
			Days since first bleed	0	5	7	12	18	
IMx HCV	3A99-20	19191 HP00	S/CO	0.49	0.51	0.53	0.49	0.51	23.6
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.20	0.22	0.24	0.37	0.60	0.31
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.21	0.23	0.24	0.31	0.44	0.23
Ortho HCV 3.0 SAv	940982	CG3CV528	OD/CO	0.12	0.15	0.13	0.33	0.77	0.34
Ortho HCV 3.0 ELISA / enhanced SAv (short incubation)	9307401	GECV028	OD/CO	0.04	0.05	0.06	0.11	0.25	0.33
Ortho HCV 3.0 ELISA / enhanced SAv (standard incubation)	9307401	GECV028	OD/CO	0.03	0.03	0.04	0.09	0.18	0.6
RIBA HCV 3.0 ^{*2}	NA	NA		Neg	Neg	Neg	Ind	Ind	
'In-house' HCV PCR ^{*2}	NA	NA	copies/ml	<100	<100	<100	<100	<100	
Chiron bDNA ^{*2}	NA	NA	copies/ml	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	

BCP anti-HCV 'false positive' seroconversion panel 6219

Product name	Product number	Lot number	Panel ID	6219-01	6219-02	6219-03	6219-04	6219-05	6219-06	6219-07	6219-08	6219-09	6219-10	6219-11	6219-12	6219-13	6219-14	Cut-off
				Days since first bleed	0	5	12	14	19	21	26	28	33	40	48	50	55	
IMx HCV	3A99-20	19191 HP00	S/CO	0.52	0.43	0.41	0.22	0.46	0.43	0.82	0.46	0.63	0.50	0.46	0.45	0.47	0.61	24.5
Monolisa anti-HCV new antigens	72307	B6E528	OD/CO	0.97	0.88	3.02	3.57	4.35	3.84	5.17	5.12	5.31	5.37	5.20	5.26	5.38	4.58	0.32
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.13	0.09	0.32	0.32	0.49	0.46	0.53	0.65	0.53	0.59	0.68	0.71	0.77	1.33	0.23
Ortho HCV 3.0 SAvE	940982	CG3CV528	OD/CO	0.26	0.33	1.89	1.84	2.81	2.10	2.92	3.35	3.40	2.94	3.35	2.82	3.25	2.59	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV028	OD/CO	0.08	0.08	0.42	0.50	0.85	0.80	1.64	1.47	1.68	2.06	2.16	2.51	2.38	1.26	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	GECV028	OD/CO	0.11	0.12	0.64	0.91	1.14	1.07	2.33	1.85	2.10	2.83	2.19	2.54	2.65	2.58	0.6
RIBA HCV 3.0 ^{*2}	NA	NA		Neg	Neg	Ind	Ind	Ind	Ind	Ind	Ind	Ind	Ind	Ind	Ind	Ind	Ind	
'In-house' HCV PCR ^{*2}	NA	NA	copies/ml	<100	<100	<100	<100	<100	<100	<100	<100	<100	<100	<100	<100	<100	<100	
Chiron bDNA ^{*2}	NA	NA	copies/ml	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	<2 x 10 ⁵	

BCP anti-HCV 'false positive' seroconversion panel 6220

Product name	Product number	Lot number	Panel ID	6220-01	6220-02	6220-03	6220-04	6220-05	6220-06	Cut-off
			Days since first bleed	0	3	8	10	18	20	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.22	0.21	0.20	0.20	2.54	1.77	0.4
IMx HCV	3A99-20	27252 HP00	S/CO	0.64	0.51	0.60	0.53	0.97	0.80	24
Monolisa anti-HCV new antigens	72307	6K533P	OD/CO	0.72	0.68	0.70	0.64	5.87	5.86	0.32
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.35	0.32	0.33	0.36	7.99	6.78	0.21
PRISM HCV * ²	6A5248	NA	S/CO	0.16	0.13	0.13	0.15	1.56	1.13	NA
Ortho HCV 3.0 SAv _e	940982	CG3CV758	OD/CO	0.17	0.14	0.14	0.13	6.60	5.55	0.34
Ortho HCV 3.0 ELISA / enhanced SAv _e (short incubation)	9307401	GECV398	OD/CO	0.03	0.03	0.02	0.03	3.34	3.22	0.35
RIBA HCV 3.0 * ²	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	
'In-house' HCV PCR * ²	NA	NA	copies/ml	Neg	Neg	Neg	Neg	Neg	Neg	
Chiron bDNA * ²	NA	NA	MEq/ml	<2x10 ⁵	<2x10 ⁵	<2x10 ⁵	<2x10 ⁵	<2x10 ⁵	2.16x10 ⁵	

BCP anti-HCV seroconversion panel 6222

Product name	Product number	Lot number	Panel ID	6222-01	6222-02	6222-03	6222-04	6222-05	6222-06	6222-07	6222-08	Cut-off
			Days since first bleed	0	2	17	19	24	26	36	40	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.17	0.14	0.14	0.13	0.14	0.10	0.12	0.21	0.38
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.03	0.04	0.04	0.04	0.03	0.29	2.65	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.19	0.17	0.20	0.16	0.16	0.20	0.58	6.71	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.21	0.14	0.17	0.17	0.15	0.12	0.33	3.20	22.2
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.02	0.03	0.03	0.02	0.04	0.06	0.14	1.15	0.23
PRISM HCV * ²	6A5248	NA	S/CO	0.07	0.07	0.07	0.06	0.06	0.10	0.34	2.89	NA
Ortho HCV 3.0 ELISA / enhanced SAv _e (short incubation)	9307401	GECV398	OD/CO	0.01	0.01	0.01	0.01	0.00	0.00	0.09	1.66	0.35
Vitros Eci anti-HCV	131 8450	0100	OD/CO	0.05	0.06	0.07	0.05	0.05	0.05	0.39	4.62	390.38
RIBA HCV 3.0 * ²	N/A	N/A		Neg	Neg	Neg	Neg	Neg	Neg	Neg	Ind	
'In-house' HCV PCR * ²	N/A	N/A	copies/ml	bld	bld	3 x 10 ⁵	6 x 10 ⁵	7 x 10 ⁵	8 x 10 ⁵	2 x 10 ⁶	5 x 10 ⁵	

BCP anti-HCV seroconversion panel 6224

Product name	Product number	Lot number	Panel ID	6224-01	6224-02	6224-03	6224-04	6224-05	6224-06	Cut-off
			Days since first bleed	0	3	7	11	19	22	
Access HCV Ab PLUS	34330	194822	S/CO	0.04	0.04	0.04	0.08	1.17	1.74	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.19	0.21	0.19	0.30	2.32	3.27	8.9
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.05	-0.03	0.03	0.04	0.91	1.56	0.21
PRISM HCV *2	6A5248	NA	S/CO	0.08	0.06	0.06	0.12	1.44	2.35	NA
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.04	0.04	0.04	0.07	1.65	2.27	402.56
RIBA HCV 3.0 *2	N/A	N/A		Neg	Neg	Neg	Neg	Neg	Neg	
'In-house' HCV PCR *2	N/A	N/A	copies/ml	2 x 10 ⁵	2 x 10 ⁵	2 x 10 ⁵	9 x 10 ⁴	3 x 10 ⁵	3 x 10 ⁵	

BCP anti-HCV seroconversion panel 9041

Product name	Product number	Lot number	Panel ID	9041-01	9041-02	9041-03	9041-04	9041-05	9041-06	9041-07	9041-08	Cut-off
			Days since first bleed	0	24	27	31	62	64	69	71	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.16	0.20	0.20	0.20	5.45	5.45	5.45	5.45	0.37
Access HCV Ab PLUS	34330	194822	S/CO	0.02	0.03	0.03	0.03	5.70	6.30	6.85	7.46	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.14	0.18	0.14	0.18	21.87	28.60	45.28	60.66	8.9
IMx HCV	3A99-20	NA	S/CO	0.11	0.10	0.11	0.03	8.36	11.92	17.37	18.99	23.6
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.09	0.05	0.05	0.04	5.68	6.07	6.16	6.26	0.41
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.00	0.01	0.01	0.01	7.30	8.03	8.21	8.78	0.34
Vitros Eci anti-HCV	131 8450	0100	OD/CO	0.05	0.05	0.05	0.05	16.7	17.5	18.3	20.3	390.38
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Neg	POS	POS	POS	POS	
Chiron bDNA *2	NA	NA	MEq/ml	<0.2	15.78	63.72	>120	72.27	66.27	21.8	11.24	

BCP anti-HCV 'false positive' seroconversion panel 9042

Product name	Product number	Lot number	Panel ID	9042-01	9042-02	9042-03	9042-04	9042-05	9042-06	Cut-off
			Days since first bleed	0	5	8	13	19	23	
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.10	0.08	0.25	0.26	0.16	0.13	0.41
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.03	0.27	2.83	3.73	3.47	2.12	0.34
RIBA HCV 3.0 *2	N/A	N/A		Neg	Ind	Ind	Ind	Ind	Ind	
Chiron bDNA *2	N/A	N/A	MEq/ml	< 0.2	< 0.2	< 0.2	< 0.2	< 0.2	< 0.2	

BCP anti-HCV 'false positive' seroconversion panel 9043

Product name	Product number	Lot number	Panel ID	9043-01	9043-02	9043-03	9043-04	9043-05	9043-06	Cut-off
			Days since first bleed	0	7	10	14	17	21	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	1.21	1.27	1.29	1.19	1.16	1.04	0.38
IMx HCV	3A99-20	NK	S/CO	0.31	0.36	0.37	0.36	0.29	0.28	22.2
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.07	0.05	0.09	0.05	0.06	0.05	0.41
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.57	0.34	0.34	0.37	0.34	0.49	0.34
RIBA HCV 3.0 *2	N/A	N/A		Ind	Ind	Ind	Ind	Ind	Ind	
Chiron bDNA *2	N/A	N/A	MEq/ml	< 0.2	< 0.2	< 0.2	< 0.2	< 0.2	< 0.2	

BCP anti-HCV seroconversion panel 9044

Product name	Product number	Lot number	Panel ID	9044-01	9044-02	9044-03	9044-04	9044-05	9044-06	Cut-off
			Days since first bleed	0	4	17	21	25	29	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.14	0.13	0.14	0.24	0.80	1.22	0.34
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.03	0.04	0.27	1.16	1.76	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.16	0.15	0.18	1.51	7.70	20.11	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.13	0.10	0.11	0.51	1.82	4.67	23.6
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.08	0.05	0.06	0.22	1.13	1.87	0.41
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.01	0.02	0.02	0.32	1.86	3.16	0.34
Vitros ECi anti-HCV	131 8450	0100	S/CO	0.06	0.06	0.06	0.87	5.30	6.71	390.38
RIBA HCV 3.0 *2	NA	NA		Neg	Neg	Neg	Neg	Ind	Ind	
Chiron bDNA *2	NA	NA	MEq/ml	105.9	52.71	77.18	71.52	72.82	48.83	

BCP Anti-HCV seroconversion panel 9045

Product name	Product number	Lot number	Panel ID	9045-01	9045-02	9045-03	9045-04	9045-05	9045-06	9045-07	9045-08	Cut-off
				Days since first bleed	0	2	7	9	26	32	37	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.08	0.11	0.11	0.12	0.14	0.15	0.26	0.81	0.37
Access HCV Ab PLUS	34330	194822	S/CO	0.03	0.03	0.03	0.02	0.03	0.06	1.05	1.46	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.13	0.11	0.13	0.14	0.11	0.28	4.02	6.80	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.13	0.09	0.10	0.09	0.10	0.15	1.18	2.27	22.2
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.03	0.04	0.05	0.04	0.03	0.07	0.73	2.40	0.38
Ortho HCV 3.0 ELISA / enhanced SAVe (short incubation)	9307401	GECV228	OD/CO	0.02	0.02	0.00	0.00	0.00	0.03	1.60	2.35	0.34
Vitros <i>Eci</i> anti-HCV	131 8450	0100	S/CO	0.06	0.05	0.05	0.06	0.06	0.05	2.30	4.71	390.38
RIBA HCV 3.0 * ²	NA	NA		Neg	Neg	Neg	Neg	Neg	Neg	Ind	Ind	
Chiron bDNA * ²	NA	NA	MEq/ml	17.73	16.42	36.19	38.07	44.86	17.78	18.36	2.32	

BCP anti-HCV seroconversion panel 9046

Product name	Product number	Lot number	Panel ID	9046-01	9046-02	9046-03	9046-04	9046-05	Cut-off
				Days since first bleed	0	69	72	76	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.11	5.93	5.93	5.93	5.93	0.34
Access HCV Ab PLUS	34330	194822	S/CO	0.05	9.03	9.35	9.25	9.15	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	0.14	97.01	84.89	87.20	83.07	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.11	24.94	24.51	26.44	23.71	23.6
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.06	5.68	5.33	4.95	5.25	0.38
Ortho HCV 3.0 ELISA / enhanced SAVe (short incubation)	9307401	GECV228	OD/CO	0.00	9.13	8.85	7.96	8.96	0.34
Vitros <i>Eci</i> anti-HCV	131 8450	0100	S/CO	0.05	22.6	23.0	23.3	23.8	390.38
RIBA HCV 3.0 * ²	N/A	N/A		Neg	POS	POS	POS	POS	
Chiron bDNA * ²	N/A	N/A	MEq/ml	<0.2	2.06	<0.2	<0.2	<0.2	

BCP anti-HCV seroconversion panel 9047

Product name	Product number	Lot number	Panel ID	9047-01	9047-02	9047-03	9047-04	9047-05	9047-06	9047-07	9047-08	9047-09	9047-10	Cut-off
				Days since first bleed	0	2	10	12	19	21	28	30	35	
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	0.21	0.22	0.22	0.22	0.28	0.22	0.35	1.07	2.85	3.52	0.37
Access HCV Ab PLUS	34330	194822	S/CO	0.07	0.07	0.10	0.06	0.06	0.06	1.79	4.57	6.31	6.25	2978761
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	0.17	0.16	0.15	0.16	0.14	0.16	10.06	38.14	61.66	62.47	8.9
IMx HCV	3A99-20	44176HP00	S/CO	0.12	0.17	0.13	0.13	0.12	0.12	2.82	12.30	20.19	20.81	22.5
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.09	0.12	0.10	0.07	0.12	0.16	0.73	4.12	5.89	6.45	0.38
Ortho HCV 3.0 ELISA / enhanced SAVe (short incubation)	9307401	GECV228	OD/CO	0.10	0.12	0.09	0.05	0.10	0.09	1.51	3.92	7.36	6.77	0.34
Vitros Eci anti-HCV	131 8450	0100	S/CO	0.05	0.07	0.06	0.07	0.05	0.06	2.67	8.11	13.8	15.6	390.38
RIBA HCV 3.0 *	N/A	N/A		Neg	Neg	Neg	Neg	Neg	Neg	Ind	Ind	Ind	POS	
Chiron bDNA *	N/A	N/A	MEq/ml	65.95	81.76	54.85	64.03	55.45	42.97	9.13	26.58	22.77	nd	

BCP anti-HCV 'false positive' seroconversion panel 9048

Product name	Product number	Lot number	Panel ID	9048-01	9048-02	9048-03	9048-04	9048-05	9048-06	9048-07	9048-08	Cut-off
				0	2	7	10	15	17	22	24	
Monolisa anti-HCV plus	72312	8D523X	OD/CO	0.73	0.82	0.57	0.72	1.13	1.26	1.01	1.01	0.41
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.49	0.56	0.33	0.45	0.76	0.38	0.68	0.29	0.34
RIBA HCV 3.0 ^{*2}	N/A	N/A		Neg	Ind	Neg	Ind	Ind	Ind	Ind	Ind	
Chiron bDNA ^{*2}	N/A	N/A	MEq/ml	<0.2	<0.2	<0.2	<0.2	<0.2	<0.2	<0.2	<0.2	

BCP anti-HCV 'false positive' seroconversion panel 9049

Product name	Product number	Lot number	Panel ID	9049-01	9049-02	9049-03	9049-04	9049-05	Cut-off
				0	2	8	12	16	
Monolisa anti-HCV plus	72311	8H018Q	OD/CO	0.70	1.85	1.22	0.67	0.45	0.28
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV228	OD/CO	0.41	2.32	0.88	0.46	0.37	0.34
RIBA HCV 3.0 ^{*2}	N/A	N/A		Ind	Ind	Ind	Ind	Ind	
Chiron bDNA ^{*2}	N/A	N/A	MEq/ml	<0.2	<0.2	<0.2	<0.2	<0.2	

BBI anti-HCV low titre panel PHV103

Product name	Product number	Lot number	Panel ID	PHV103-01	PHV103-02	PHV103-03	PHV103-04	PHV103-05	PHV103-06	PHV103-07	PHV103-08	PHV103-09	PHV103-10	PHV103-11	PHV103-12	PHV103-13	PHV103-14	PHV103-15	Cut-off	
			Expected results	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	neg	POS	POS	POS	POS		POS
Abbott HCV 3rd generation EIA	7A16-23	93292 HP00	OD/CO	3.96	5.95	3.45	6.51	7.75	1.08	0.66	4.41	2.95	0.18	5.14	2.69	2.72	1.20	8.16	0.25	
Access anti-HCV	34310	590802	S/CO	1.31	18.21	4.16	1.67	4.95	1.97	2.93	2.30	1.34	0.34	14.67	1.29	2.25	1.19	173.96	42593	
IMx HCV	3A99-20	95982 HP00	S/CO	10.78	21.64	20.77	7.31	10.17	1.73	10.15	18.08	11.53	0.50	1.22	24.70	4.56	6.06	12.61	34.6	
Monolisa anti-HCV new antigens	72306	4L017X	OD/CO	1.71	2.13	3.72	6.14	7.35	3.37	0.71	1.65	5.03	0.25	2.56	3.71	1.10	4.31	4.74	0.4	
Monolisa anti-HCV plus	72311	6C501.U	OD/CO	4.87	5.65	4.15	9.32	9.95	5.60	1.32	3.87	6.55	0.32	5.86	5.12	4.19	4.14	6.61	0.27	
PRISM HCV	6A5248	N/A	S/CO	2.59	3.65	2.45	3.27	5.79	3.49	2.23	2.24	2.83	0.09	4.25	2.20	3.62	1.40	4.13	**	
Ortho HCV 3.0 ELISA	930700	CG3CV058	OD/CO	10.21	9.26	7.71	10.07	10.09	10.23	2.82	6.23	10.23	0.03	10.22	10.22	7.94	2.95	9.92	0.33	
Ortho HCV 3.0 SAve	940982	CG3CV738	OD/CO	4.55	4.23	2.50	9.01	9.01	2.87	2.81	2.41	4.23	0.02	5.83	4.04	2.50	0.64	9.01	0.33	
Ortho HCV 3.0 ELISA / enhanced SAve (short incubation)	9307401	GECV028	OD/CO	5.08	4.65	3.90	8.49	≥ 9.01	5.77	5.86	3.75	6.00	0.02	6.69	5.23	4.65	1.70	≥ 9.01	0.33	
Ortho HCV 3.0 ELISA / enhanced SAve (standard incubation)	9307401	GECV028	OD/CO	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	≥ 4.88	0.02	≥ 4.88	≥ 4.88	4.70	2.80	≥ 4.88	0.62	
RIBA HCV 3.0 *	N/A	N/A		POS	POS	POS	POS	POS	POS	POS	POS	POS	Ind	Neg	POS	POS	POS	Ind	POS	

BBI anti-HCV low titre panel PHV104

Product name	Product number	Lot number	Panel ID Expected results	PHV104-01	PHV104-02	PHV104-03	PHV104-04	PHV104-05	PHV104-06	PHV104-07	PHV104-08	PHV104-09	PHV104-10	PHV104-11	PHV104-12	PHV104-13	PHV104-14	PHV104-15	Cut-off
				POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	neg	POS	POS	
Access HCV Ab PLUS	34330	194822	S/CO	2.23	10.00	2.59	8.66	4.44	9.10	7.46	1.06	3.41	2.40	1.83	0.03	1.52	2.19	7.63	2978761
AxSYM [®] HCV version 3.0	3B44-20	65113LU00	S/CO	2.11	78.18	5.64	58.41	7.25	74.30	22.82	2.68	3.72	5.27	2.64	0.31	3.08	3.56	51.35	8.9
IMx HCV	3A99-20	22210HP00	S/CO	3.44	28.06	16.67	7.23	0.60	4.01	15.10	9.99	26.60	23.50	12.62	0.40	8.42	28.31	4.15	25.2
Monolisa anti-HCV new antigens	72307	B:6F529.X	OD/CO	3.35	12.98	5.09	9.81	1.52	7.41	7.17	3.29	2.93	5.94	1.33	0.15	1.28	3.49	7.57	0.26
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	0.62	12.27	3.66	10.71	0.73	10.98	8.44	2.82	3.48	4.52	2.23	0.03	2.00	3.24	8.24	0.21
Monolisa anti-HCV plus Version 2	72318	9M513U	OD/CO	3.20	12.40	5.23	12.35	2.17	10.73	9.64	4.23	4.97	6.53	3.23	0.15	3.72	5.76	7.99	0.23
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	1.62	13.42	2.54	13.42	2.01	13.42	10.15	0.99	3.80	3.29	1.04	0.02	1.79	1.68	8.39	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	CEGV038	OD/CO	1.89	8.98	3.25	8.98	2.39	8.13	7.84	1.79	3.66	4.35	2.06	0.08	2.52	2.81	7.08	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	CEGV038	OD/CO	1.87	4.87	3.66	4.87	0.86	4.87	4.87	2.07	3.69	3.87	2.11	0.04	2.67	3.02	4.87	0.62
Vitros Eci anti-HCV	131 8450	0100	S/CO	10.8	21.4	8.63	21.1	6.95	19.3	17.3	4.69	13.1	11.3	7.21	0.06	6.43	6.77	11.9	390.38
RIBA HCV 3.0 *	930780	MLB603		POS	POS	Ind	POS	POS	POS	POS	POS	POS	Ind	POS	Neg	POS	POS	POS	
AMPLICOR HCV monitor test *	87302	82206	copies/ml	BLD	1 x 10 ⁵	BLD	6 x 10 ⁵	1 x 10 ⁵	1 x 10 ⁵	1 x 10 ⁴	BLD	BLD	2 X 10 ⁴	BLD	NT	2 X 10 ⁴	BLD	1 X 10 ⁵	

BBI anti-HCV mixed titre panel PHV204

Product name	Product number	Lot number	Panel ID Expected results	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	PHV204	Cut-off
				-01	-02	-03	-04	-05	-10	-11	-12	-13	-14	-15	-16	-17	-18	-19	-20	-21	-22	-23	-24	-25	
Access HCV Ab PLUS	34330	194822	S/CO	9.42	5.78	4.64	8.21	9.89	0.02	10.39	6.67	4.34	11.12	8.43	3.07	8.70	10.16	6.88	8.69	7.70	8.95	0.03	4.59	3.95	3E+06
AxSYM® HCV version 3.0	3B44-20	65113LU00	S/CO	54.52	39.72	19.83	33.95	81.49	0.17	119.27	13.80	5.01	70.53	43.12	6.92	45.71	69.17	36.00	9.18	81.37	48.12	0.31	10.91	8.54	8.9
IMx HCV	3A99-20	22210 HP00	S/CO	13.31	2.95	26.34	57.17	26.38	0.59	15.73	6.10	6.95	21.20	11.57	9.96	11.71	30.05	3.10	29.01	1.29	28.64	0.44	32.04	43.13	21.4
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	9.26	6.90	7.67	9.64	10.67	0.05	11.94	9.72	4.51	11.09	10.14	2.25	9.93	10.79	6.66	8.30	7.01	10.12	0.14	4.84	5.59	0.21
Ortho HCV 3.0 SAvE	940982	CG3CV738	OD/CO	8.90	8.90	8.14	8.90	8.90	0.02	8.90	8.90	4.55	8.90	8.90	0.81	8.90	8.90	8.90	8.90	8.90	8.90	0.03	4.95	5.58	0.34
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	CEGV038	OD/CO	8.50	8.34	7.10	8.51	8.98	0.05	8.98	7.45	4.54	8.98	8.33	3.21	8.13	8.98	8.32	8.07	7.31	8.41	0.06	5.70	5.05	0.33
Ortho HCV 3.0 ELISA / enhanced SAvE (standard incubation)	9307401	CEGV038	OD/CO	4.87	4.87	4.87	4.87	4.87	0.04	4.87	4.87	3.63	4.87	4.87	3.54	4.87	4.87	4.87	4.87	4.87	4.87	0.04	4.87	4.65	0.62
Vitros Eci anti-HCV	131 8450	0100	S/CO	24.6	17.4	14.1	20.8	22.2	0.06	24.9	17.8	14.9	26.0	19.9	9.52	16.4	23.5	17.5	23.9	18.0	23.0	0.05	14.5	14.3	390.38
RIBA HCV 3.0 *	930780	MJJ879		POS	POS	POS	POS	POS	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	Neg	POS	POS	

BBI Worldwide anti-HCV performance panel WWHV301

Product name	Product number	Lot number	Panel ID	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	WWHV	Cut-off
				301-01	301-02	301-03	301-04	301-05	301-06	301-07	301-08	301-09	301-10	301-11	301-12	301-13	301-14	301-15	301-16	301-17	301-18	301-19	301-20	
				Country of origin	Argentina	Argentina	Argentina	Argentina	Argentina	Uganda	Uganda	Ghana	China	China	China	China	China	Egypt	Egypt	Egypt	Egypt	U.S.	U.S.	
Expected result	POS	POS	POS	POS	Neg	POS	POS	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS	POS		
Abbott HCV 3rd generation EIA	7A16-23	43309HP00	OD/CO	5.45	5.45	5.45	5.45	0.21	5.45	5.45	0.46	5.45	5.45	4.88	5.45	5.45	5.45	5.45	5.45	5.45	5.45	1.88	5.45	0.37
Monolisa anti-HCV new antigens	72307	7F536P	OD/CO	8.66	8.28	8.54	7.15	0.11	7.12	6.93	0.43	8.20	8.24	7.84	8.09	7.85	9.50	8.65	7.82	5.46	8.27	5.45	7.82	0.37
Monolisa anti-HCV plus	72312	8H018Q	OD/CO	9.27	9.49	10.44	10.37	0.01	11.77	8.28	0.23	9.80	11.36	7.34	10.18	10.96	9.54	10.47	11.53	7.38	9.41	5.94	8.48	0.21
Ortho HCV 3.0 ELISA / enhanced SAvE (short incubation)	9307401	GECV118	OD/CO	8.18	9.46	8.50	9.35	0.01	7.41	7.60	0.06	7.98	8.94	7.80	8.80	9.41	8.85	8.85	8.83	6.00	8.61	5.29	7.61	0.34
RIBA HCV 3.0 *	930780	TXE225-5		POS	POS	POS	Ind	Neg	POS	POS	Neg	POS	POS	POS	POS	POS	POS	POS	POS	POS	Ind	POS	POS	POS
Murex HCV Serotyping 1 – 6	HC02	F05110		1	NTyp	3	3	Neg	4	2	NT	1	1	1	2	1,2	(3)	(4)	(4)	(4)	1	NTyp	1	
Innogenetics INNO- LIPA	K-1045	6051549		1b	1b	3a/b	2a/c	NT	4c/d	NTyp	NT	1b, 2a/c	2	1b	2	1a/b, 2a/c	3a	4	4h	NTyp	1b	1a	1a	
AMPLICOR HCV monitor test *	87382	82337	copies/ml	> 5 x 10 ⁵	3 x 10 ⁵	6 x 10 ⁴	9 x 10 ⁴	NT	4 x 10 ³	BLD	NT	3 x 10 ³	4 x 10 ³	4 x 10 ³	2 x 10 ⁴	1 x 10 ⁵	1 x 10 ⁵	6 x 10 ⁴	2 x 10 ⁴	BLD	>5 X 10 ⁵	3 X 10 ⁵	1 X 10 ⁴	

RIBA HCV 3.0 immunoblot patterns for BBI anti-HCV seroconversion panel PHV901 - 907

Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result	Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result
		c100	c33	c22	NS5					c100	c33	c22	NS5		
PHV901-01	0	-	-	-	-	neg	PHV905-01	0	-	-	-	-	neg		
PHV901-02	65	-	-	-	-	neg	PHV905-02	4	-	-	-	-	neg		
PHV901-03	97	3+	-	-	-	POS	PHV905-03	7	-	-	-	-	neg		
PHV901-04	99	3+	4+	-	-	POS	PHV905-04	11	-	1+	-	-	ind		
PHV901-05	104	3+	4+	-	-	POS	PHV905-05	14	-	1+	-	-	ind		
PHV901-06	106	3+	4+	-	-	POS	PHV905-06	18	-	1+	±	-	ind		
PHV901-07	131	4+	4+	-	-	POS	PHV905-07	21	-	2+	1+	-	POS		
PHV901-08	139	4+	4+	-	-	POS	PHV905-08	25	-	4+	4+	-	POS		
PHV901-09	159	4+	4+	-	-	POS	PHV905-09	28	-	4+	4+	-	POS		
PHV901-10	166	4+	4+	-	-	POS									
PHV901-11	203	4+	4+	±	-	POS	PHV906-01	0	±	4+	-	-	ind		
							PHV906-02	2	±	4+	-	-	ind		
PHV902-01	0	-	-	-	-	neg	PHV906-03	7	2+	4+	-	-	POS		
PHV902-02	2	-	-	-	-	neg	PHV906-04	10	3+	4+	-	-	POS		
PHV902-03	7	-	2+	-	-	ind	PHV906-05	14	4+	4+	-	-	POS		
PHV902-04	9	±	2+	-	-	ind	PHV906-06	17	4+	4+	-	-	POS		
PHV902-05	14	±	4+	±	±	ind	PHV906-07	21	4+	4+	-	-	POS		
PHV902-06	16	±	4+	±	±	ind									
PHV902-07	21	1+	4+	1+	±	POS	PHV907-01	0	-	-	-	-	neg		
							PHV907-02	4	-	-	-	-	neg		
PHV903-01	0	-	-	±	±	neg	PHV907-03	7	-	-	-	-	neg		
PHV903-02	5	-	-	2+	±	ind	PHV907-04	13	-	-	1+	-	ind		
PHV903-03	7	-	±	3+	±	ind	PHV907-05	18	-	±	4+	-	ind		
PHV903-04	12	-	±	2+	±	ind	PHV907-06	21	-	1+	4+	-	POS		
PHV903-05	14	±	1+	3+	±	POS	PHV907-07	164	4+	4+	4+	3+	POS		
PHV903-06	19	±	4+	4+	±	POS									
PHV903-07	21	±	4+	4+	±	POS									
PHV903-08	26	±	4+	4+	±	POS									
PHV904-01	0	-	-	-	-	neg									
PHV904-02	2	-	-	-	-	neg									
PHV904-03	7	-	-	-	-	neg									
PHV904-04	9	-	±	-	-	neg									
PHV904-05	14	-	1+	-	-	ind									
PHV904-06	21	-	2+	-	-	ind									
PHV904-07	23	-	3+	-	-	ind									

RIBA HCV 3.0 immunoblot patterns for BBI anti-HCV seroconversion panel PHV908 - 915

Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result	Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result
		c100	c33	c22	NS5	Result				c100	c33	c22	NS5	Result	
PHV908-01	0	-	-	-	-	neg	PHV912-01	0	-	-	-	-	neg		
PHV908-02	3	-	-	-	-	neg	PHV912-02	4	-	-	-	-	neg		
PHV908-03	5	-	-	-	-	neg	PHV912-03	7	±	-	4+	-	ind		
PHV908-04	11	±	±	-	-	neg									
PHV908-05	13	1+	1+	-	-	POS	PHV913-01	0	-	-	-	-	neg		
PHV908-06	19	2+	2+	-	-	POS	PHV913-02	2	-	-	-	-	neg		
PHV908-07	25	3+	4+	-	-	POS	PHV913-03	7	-	-	2+	-	ind		
PHV908-08	27	3+	4+	-	-	POS	PHV913-04	9	-	±	2+	-	ind		
PHV908-09	32	3+	4+	-	-	POS									
PHV908-10	35	3+	4+	-	-	POS	PHV914-01	0	-	-	-	-	neg		
PHV908-11	41	3+	4+	-	-	POS	PHV914-02	5	-	-	-	-	neg		
PHV908-12	45	3+	4+	-	-	POS	PHV914-03	9	-	-	-	-	neg		
PHV908-13	48	3+	4+	-	-	POS	PHV914-04	12	-	-	-	-	neg		
							PHV914-05	16	-	-	2+	-	ind		
PHV909-01	0	-	-	-	-	neg	PHV914-06	19	-	-	2+	-	ind		
PHV909-02	28	-	-	1+	±	ind	PHV914-07	24	-	±	4+	-	ind		
PHV909-03	30	-	-	2+	±	ind	PHV914-08	30	-	3+	4+	-	POS		
							PHV914-09	33	-	3+	4+	-	POS		
PHV910-01	0	-	-	-	-	neg									
PHV910-02	4	-	-	-	-	neg	PHV915-01	0	-	±	-	-	neg		
PHV910-03	8	±	1+	3+	-	POS	PHV915-01	5	-	1+	-	-	ind		
PHV910-04	11	1+	3+	4+	-	POS	PHV915-01	12	-	2+	-	-	ind		
PHV910-05	15	4+	4+	4+	-	POS	PHV915-01	14	-	3+	-	-	ind		
PHV911-01	0	-	-	-	-	neg									
PHV911-02	3	-	-	-	-	neg									
PHV911-03	14	-	1+	3+	-	POS									
PHV911-04	21	2+	4+	4+	-	POS									
PHV911-05	24	3+	4+	4+	-	POS									

RIBA HCV 3.0 immunoblot patterns for BCP anti-HCV seroconversion panels 6211 - 6216 and 6222

Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result	Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result
		c100	c33	c22	NS5	Result				c100	c33	c22	NS5	Result	
6211-31	150	-	-	-	-	neg	6214-01	0	-	-	-	-	neg		
6211-32	154	-	-	-	-	neg	6214-01	2	-	-	-	-	neg		
6211-33	157	-	-	-	-	neg	6214-01	8	-	-	-	-	neg		
6211-34	161	-	-	-	-	neg	6214-01	10	-	-	-	-	neg		
6211-35	164	-	-	-	-	neg	6214-01	16	-	-	-	-	neg		
6211-36	168	-	-	-	-	neg	6214-01	18	-	-	-	-	neg		
6211-37	171	-	-	-	-	neg	6214-01	23	-	±	-	-	neg		
6211-38	182	-	2+	-	-	ind	6214-01	25	±	±	-	-	neg		
6211-39	186	1+	3+	-	-	POS	6214-01	30	±	2+	-	-	ind		
6211-40	189	3+	4+	-	-	POS	6214-01	32	±	3+	-	-	ind		
6212-01	0	-	-	-	-	neg	6214-01	49	2+	4+	-	-	POS		
6212-02	12	-	±	-	-	neg	6214-01	53	2+	4+	-	-	POS		
6212-03	14	-	±	-	-	neg	6214-01	56	2+	4+	-	-	POS		
6212-04	23	-	1+	-	-	ind	6215-01	0	-	-	-	-	neg		
6212-05	26	-	1+	-	-	ind	6215-02	3	-	-	-	-	neg		
6212-06	32	-	1+	-	-	ind	6215-03	10	-	-	-	-	neg		
6212-07	37	-	1+	-	-	ind	6215-04	20	-	±	4+	-	ind		
6212-08	53	-	4+	-	-	ind	6216-01	0	-	-	-	-	neg		
6212-09	55	-	4+	-	-	ind	6216-02	3	-	-	-	-	neg		
6213-01	0	-	-	-	-	neg	6216-03	8	-	-	-	-	neg		
6213-01	2	-	-	-	-	neg	6216-04	10	-	-	-	-	neg		
6213-01	8	-	-	-	-	neg	6216-05	15	-	-	-	-	neg		
6213-01	11	-	-	-	-	neg	6216-06	17	-	-	-	-	neg		
6213-01	15	-	-	-	-	neg	6216-07	23	-	-	3+	-	ind		
6213-01	18	-	-	-	-	neg	6222-01	0	-	-	-	-	neg		
6213-01	28	-	-	-	-	neg	6222-01	2	-	-	-	-	neg		
6213-01	30	-	-	-	-	neg	6222-01	17	-	-	-	-	neg		
6213-01	35	-	-	-	-	neg	6222-01	19	-	-	-	-	neg		
6213-01	37	-	±	-	-	neg	6222-01	24	-	-	-	-	neg		
6213-01	43	-	3+	2+	-	POS	6222-01	26	-	-	-	-	neg		
6213-01	46	±	3+	3+	-	POS	6222-01	36	-	±	±	-	neg		
							6222-01	40	-	2+	±	-	ind		

RIBA HCV 3.0 immunoblot patterns for BCP anti-HCV seroconversion panels 9041, 9044 - 9046 and 9047

Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result	Panel ID	Days since first bleed	RIBA HCV 3.0 (BBI data)					Result
		c100	c33	c22	NS5					c100	c33	c22	NS5		
9041-01	0	-	-	-	-		neg	9046-01	0	-	-	-	-		neg
9041-02	24	-	-	-	-		neg	9046-01	69	2+	4+	4+	-		POS
9041-03	27	-	-	-	-		neg	9046-01	72	3+	4+	4+	-		POS
9041-04	31	-	-	-	-		neg	9046-01	76	3+	4+	4+	-		POS
9041-05	62	1+	4+	±	±		POS	9046-01	79	3+	4+	4+	-		POS
9041-06	64	1+	4+	±	±		POS								
9041-07	69	2+	4+	1+	3+		POS	9047-01	0	-	-	-	-		neg
9041-08	71	3+	4+	3+	3+		POS	9047-01	2	-	-	-	-		neg
								9047-01	10	-	-	-	-		neg
9044-01	0	-	-	-	-		neg	9047-01	12	-	-	-	-		neg
9044-02	4	-	-	-	-		neg	9047-01	19	-	-	-	-		neg
9044-03	17	-	-	-	-		neg	9047-01	21	-	-	-	-		neg
9044-04	21	-	±	-	-		neg	9047-01	28	-	2+	-	-		ind
9044-05	25	-	2+	-	±		ind	9047-01	30	-	4+	-	-		ind
9044-06	29	±	3+	-	±		ind	9047-01	35	±	4+	-	-		ind
								9047-01	37	2+	4+	±	±		POS
9045-01	0	-	-	-	-		neg								
9045-02	2	-	-	-	-		neg								
9045-03	7	-	-	-	-		neg								
9045-04	9	-	-	-	-		neg								
9045-05	26	-	-	-	-		neg								
9045-06	32	-	-	-	-		neg								
9045-07	37	-	1+	-	-		ind								
9045-08	41	±	2+	-	-		ind								

RIBA HCV 3.0 immunoblot patterns for BBI anti-HCV performance panels PHV103 - 104 and PHV203 - 204

Panel ID	Expected result	RIBA HCV 3.0 (BBI data)					Result	Panel ID	Expected result	RIBA HCV 3.0 (BBI data)					Result
		c100	c33	c22	NS5					c100	c33	c22	NS5		
PHV103-01	POS	2+	2+	±	-	POS	PHV104-01	POS	1+	±	1+	-	POS		
PHV103-02	POS	±	2+	4+	1+	POS	PHV104-02	POS	4+	4+	±	2+	POS		
PHV103-03	POS	±	2+	2+	-	POS	PHV104-03	POS	±	3+	±	±	ind		
PHV103-04	POS	1+	4+	-	-	POS	PHV104-04	POS	4+	4+	-	4+	POS		
PHV103-05	POS	2+	4+	-	-	POS	PHV104-05	POS	±	1+	3+	-	POS		
PHV103-06	POS	4+	4+	±	-	POS	PHV104-06	POS	±	4+	3+	4+	POS		
PHV103-07	POS	1+	1+	-	±	POS	PHV104-07	POS	4+	4+	-	4+	POS		
PHV103-08	POS	1+	1+	3+	-	POS	PHV104-08	POS	2+	1+	-	-	POS		
PHV103-09	POS	±	2+	-	-	ind	PHV104-09	POS	±	1+	2+	±	POS		
PHV103-10	neg	-	-	-	-	neg	PHV104-10	POS	±	2+	-	±	ind		
PHV103-11	POS	2+	4+	2+	-	POS	PHV104-11	POS	2+	3+	2+	±	POS		
PHV103-12	POS	4+	3+	-	-	POS	PHV104-12	neg	-	-	-	-	neg		
PHV103-13	POS	±	2+	1+	-	POS	PHV104-13	POS	3+	1+	-	±	POS		
PHV103-14	POS	±	4+	-	±	ind	PHV104-14	POS	1+	2+	±	-	POS		
PHV103-15	POS	±	4+	4+	-	POS	PHV104-15	POS	4+	4+	±	-	POS		
PHV203-01	POS	2+	±	1+	-	POS	PHV204-01	POS	1+	4+	4+	4+	POS		
PHV203-02	POS	-	±	1+	-	ind	PHV204-02	POS	4+	4+	-	4+	POS		
PHV203-03	POS	3+	1+	-	-	POS	PHV204-03	POS	1+	4+	-	-	POS		
PHV203-04	POS	±	±	2+	-	ind	PHV204-04	POS	4+	4+	±	4+	POS		
PHV203-05	neg	-	-	-	±	neg	PHV204-05	POS	2+	4+	4+	4+	POS		
PHV203-06	POS	1+	2+	2+	1+	POS	PHV204-06	POS	4+	-	4+	±	POS		
PHV203-07	POS	1+	2+	2+	1+	POS	PHV204-07	POS	1+	2+	4+	-	POS		
PHV203-08	POS	±	2+	-	-	ind	PHV204-08	POS	2+	4+	4+	±	POS		
PHV203-09	POS	±	±	2+	-	ind	PHV204-09	POS	3+	4+	-	-	POS		
PHV203-10	POS	±	±	2+	-	ind	PHV204-10	neg	-	-	-	-	neg		
PHV203-11	POS	2+	2+	-	2+	POS	PHV204-11	POS	4+	4+	-	4+	POS		
PHV203-12	POS	±	1+	1+	±	POS	PHV204-12	POS	2+	4+	1+	-	POS		
PHV203-13	POS	±	1+	1+	-	POS	PHV204-13	POS	3+	2+	2+	±	POS		
PHV203-14	POS	2+	±	4+	-	POS	PHV204-14	POS	±	4+	4+	-	POS		
PHV203-15	neg	-	-	-	-	neg	PHV204-15	POS	2+	4+	-	-	POS		
PHV203-16	POS	4+	4+	3+	-	POS	PHV204-16	POS	2+	4+	±	-	POS		
PHV203-17	POS	2+	2+	2+	-	POS	PHV204-17	POS	2+	4+	-	-	POS		
PHV203-18	POS	4+	4+	4+	4+	POS	PHV204-18	POS	4+	4+	4+	2+	POS		
PHV203-19	POS	3+	4+	4+	4+	POS	PHV204-19	POS	4+	4+	-	±	POS		
PHV203-20	POS	2+	2+	±	2+	POS	PHV204-20	POS	±	1+	4+	±	POS		
PHV203-21	POS	4+	4+	4+	4+	POS	PHV204-21	POS	4+	4+	4+	±	POS		
PHV203-22	POS	4+	4+	4+	4+	POS	PHV204-22	POS	2+	4+	3+	-	POS		
PHV203-23	POS	2+	2+	-	±	POS	PHV204-23	neg	-	-	-	-	neg		
PHV203-24	POS	-	±	1+	-	ind	PHV204-24	POS	3+	3+	-	-	POS		
PHV203-25	POS	-	-	-	-	neg	PHV204-25	POS	2+	4+	-	2+	POS		

RIBA HCV 3.0 immunoblot patterns for worldwide HCV performance panel WWHV301

Panel ID	Expected result	RIBA HCV 3.0 (BBI data)				Result
		c100	c33	c22	NS5	
WWHV301-01	POS	3+	4+	4+	3+	POS
WWHV301-02	POS	-	2+	4+	-	POS
WWHV301-03	POS	4+	3+	4+	4+	POS
WWHV301-04	POS	4+	4+	4+	4+	POS
WWHV301-05	neg	-	-	-	-	neg
WWHV301-06	POS	4+	4+	±	-	POS
WWHV301-07	POS	-	4+	±	2+	POS
WWHV301-08	neg	-	-	-	-	neg
WWHV301-09	POS	4+	4+	4+	2+	POS
WWHV301-10	POS	4+	4+	4+	2+	POS
WWHV301-11	POS	2+	4+	±	-	POS
WWHV301-12	POS	4+	4+	4+	4+	POS
WWHV301-13	POS	4+	4+	4+	4+	POS
WWHV301-14	POS	2+	2+	4+	-	POS
WWHV301-15	POS	2+	4+	4+	-	POS
WWHV301-16	POS	4+	4+	3+	4+	POS
WWHV301-17	POS	±	±	4+	-	ind
WWHV301-18	POS	1+	3+	3+	-	POS
WWHV301-19	POS	1+	4+	-	-	POS
WWHV301-20	POS	1+	4+	4+	2+	POS

References

1. **Perry KR, Giles RE, Burgess C, Kenny C, Sallett K, Parry JV** (1999): Anti-HCV commercial panel data - Comparative performance data for anti-HCV assays using commercial seroconversion and other panels.
Medical Devices Agency. MDA/99/49
2. **Burgess C, Perry KR, Parry JV** (2001): An evaluation of AxSYM® HCV version 3.0.
Medical Devices Agency. MDA 01007
3. **Kenny C, Perry KR, Sallett K, Parry JV** (2001): An evaluation of Vitros *ECi* anti-HCV.
Medical Devices Agency. MDA 01122
4. **Delieu E, Keith R. Perry, John V. Parry** (2002): An evaluation of Access® HCV Ab PLUS
Medical Devices Agency. In press
5. **Giles RE, Kenny C, Sallett K, Perry KR, Burgess C, Parry JV** (1999): Anti-HIV commercial panel data - Comparative performance data for anti-HIV assays using commercial seroconversion and other panels.
Medical Devices Agency. MDA/99/27
6. **Giles RE, Kenny C, Sallett K, Perry KR, Burgess C, Parry JV** (2000): Anti-HIV commercial panel data (update 1) – Comparative performance data for anti-HIV assays using commercial seroconversion and other panels.
Medical Devices Agency. MDA/2000/54
7. **Giles RE, Burgess C, Kenny C, Sallett K, Perry KR, Parry JV** (1999): HBsAg commercial panel data - Comparative performance data for HBsAg assays using commercial seroconversion and other panels.
Medical Devices Agency. MDA/99/48
8. **Burgess C, Perry KR, Sallett K, Parry JV** (2002): HBsAg commercial panel data (update 1) – Comparative performance data for HBsAg assays using commercial seroconversion and other panels.
Medical Devices Agency. In press
9. **Mortimer PP, Mouldale HJ, Parry JV, Oldham LJ, Pereira MS, Mortimer JY, Kennedy DA, Lister PA** (1985): Public Health Laboratory Service and Department of Health and Social Security evaluation of five commercial anti-HTLV III/LAV assay kits.
DHSS Publications. STB3A/85/40
10. **Mortimer PP, Parry JV, Mortimer JY** (1985): Which anti-HTLV III/LAV assays for screening and confirmatory testing?
Lancet ii: 873 - 877

11. **Perry KR, Palmer D, McAlpine L, Mortimer PP, Parry JV** (1995): Ten anti-HCV screening assays.
Medical Devices Agency. MDA/95/03
12. **Perry KR, Parry JV** (1996): Sanofi Diagnostics Pasteur ACCESS® anti-HCV automated immunoassay (plus update data on five other anti-HCV assays).
Medical Devices Agency. MDA/96/26
13. **Giles RE, Perry KR, Parry JV** (1997): Abbott PRISM™ automated anti-HCV assay system.
Medical Devices Agency. MDA/97/72
14. **Dussaix E, Charnaux N, Laurent-Puig P, Chopineau S, Laurian Y, Buffet C** (1994): Analysis of sera indeterminate by Ortho-HCV RIBA-2 by using three confirmatory assays for anti-hepatitis C virus antibody.
Journal of Clinical Microbiology **32**: 2071 - 2075
15. **Zaaijer HL, Vrieling H, van Exel-Oehlers PJ, Cuypers HTM, Lelie PN** (1994): Confirmation of hepatitis C infection - a comparison of five immunoblot assays.
Transfusion **34**: 603 - 607
16. **Dow BC, Buchanan I, Munro H, Follett EAC, Davidson F, Prescott LE, Yap PL, Simmonds P** (1996): Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors.
Journal of Medical Virology **49**: 132 - 136

■ Contact details for manufacturer and/or UK agent

Abbott/Murex Laboratories Ltd

Abbott House
Norden Road
Maidenhead
Berkshire
SL6 4XF

Tel: 01628 784041

Fax: 01628 644205

Products: Abbott HCV 3rd Generation EIA (7A16-23)
 AxSYM® HCV version 3 (3B44-20)
 IMx HCV (3A99-20)
 PRISM™ automated HCV assay (6A5248)

Beckman Coulter

Oakley Court
Kingsmead Business Park
London Road
High Wycombe
Bucks
HP11 1JU
(Access® manufacturer)

Tel: 01494 441181

Fax: 01494 447558

BioRad Laboratories (UK) Ltd

BioRad House
Maylands Avenue
Hemel Hempstead
Herts
HP2 7TD

Tel: 020 8328 2209

Fax: 020 8328 2550

Product: Access® anti-HCV automated immunoassay (34310) - discontinued
 Access® HCV Ab Plus automated immunoassay (34330)
 Monolisa anti-HCV New Antigens (72306)
 Monolisa anti-HCV Plus (72312)

Ortho-Clinical Diagnostics

Mandeville House
62 The Broadway
Amersham
Buckinghamshire
HP7 0HJ

Tel: 01494 431717
Tel:01494 545600
Fax 01494 431165

Product: Ortho HCV 3.0 ELISA (930700)
 Ortho HCV 3.0 SAve (940982)
 Ortho HCV 3.0 enhanced SAve (9307401)
 Vitros *ECi* anti-HCV (131 8450)

■ How to obtain MDA evaluation reports

MDA evaluation reports are published by the Medical Devices Agency, an Executive Agency of the Department of Health. They are available free of charge to the UK National Health Service (NHS), and are for sale to commercial organisations and other interested parties. A free catalogue of available reports can be obtained from the Orders Department, or downloaded from the MDA web site:

<http://www.medical-devices.gov.uk>

Ordering

Send your order to the address given below, stating the number, title and quantity of each report required. Your reports will be dispatched by second class post the following working day. If you are not a representative of the NHS, you will be invoiced separately. Non-NHS customers are reminded that it is not possible to offer refunds for reports ordered in error.

Orders Department
Room 1207
Medical Devices Agency
Hannibal House
Elephant and Castle
London
SE1 6TQ

Tel: 020 7972 8181
Fax: 020 7972 8105
E-mail: dep@medical-devices.gov.uk

Enquiries

General enquiries should be directed to the MDA Orders Department, as above. Technical enquiries regarding this report should be addressed to Dr Keith Perry at MiDAS

Tel: 020 8200 4400 ext 3949
Fax: 020 8200 1569
E-mail: kperry@phls.org.uk

ISBN 1 84182 519 0
36 26796 1